

Coronary Heart Disease Prediction From Lipoprotein C Lipoprotein(a), Apolipoproteins A-I and B, and HDL Der

Circulation

104, 1108-1113

DOI: [10.1161/hc3501.095214](https://doi.org/10.1161/hc3501.095214)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effect of Ciprofibrate on Lipoproteins, Fibrinogen, Renal Function, and Hepatic Enzymes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 219-226.	1.0	35
3	Atherosclerosis: cell biology and lipoproteins. <i>Current Opinion in Lipidology</i> , 2002, 13, 347-349.	1.2	7
4	Hyperlipidaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2002, 13, 343-345.	1.2	1
5	Association Between Serum Apolipoprotein CII Concentration and Coronary Heart Disease. <i>Preventive Medicine</i> , 2002, 35, 42-47.	1.6	29
6	Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: the Northern Manhattan stroke study. <i>Atherosclerosis</i> , 2002, 165, 317-325.	0.4	23
7	How, when, and why to use apolipoprotein B in clinical practice. <i>American Journal of Cardiology</i> , 2002, 90, 48-54.	0.7	51
8	Lipoprotein abnormalities related to women's health. <i>American Journal of Cardiology</i> , 2002, 90, 77-84.	0.7	80
9	Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. <i>American Journal of Cardiology</i> , 2002, 90, 30-47.	0.7	162
10	Lipoprotein heterogeneity: diagnostic and therapeutic implications. <i>American Journal of Cardiology</i> , 2002, 90, 1-10.	0.7	29
11	Searching for the mountains of the moon: Genome scans for atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2002, 4, 169-175.	2.0	0
12	Update on the role of triglycerides as a risk factor for coronary heart disease. <i>Current Atherosclerosis Reports</i> , 2002, 4, 414-418.	2.0	8
13	Goals of statin therapy: Three viewpoints. <i>Current Atherosclerosis Reports</i> , 2002, 4, 26-33.	2.0	5
14	Hypertriglyceridemia and risk of coronary heart disease. <i>Current Cardiology Reports</i> , 2002, 4, 488-493.	1.3	47
15	Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred. <i>Journal of Human Genetics</i> , 2002, 47, 0656-0664.	1.1	37
16	High-density lipoprotein subpopulations in pathologic conditions. <i>American Journal of Cardiology</i> , 2003, 91, 12-17.	0.7	82
17	Association of lipoprotein(a), insulin resistance, and reproductive hormones in a multiethnic cohort of pre- and perimenopausal women (The SWAN Study). <i>American Journal of Cardiology</i> , 2003, 92, 533-537.	0.7	30
18	Changing sex ratio in acute coronary heart disease: data from Swedish national registers 1984-99. <i>Journal of Internal Medicine</i> , 2003, 253, 301-310.	2.7	16
19	Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial. <i>European Journal of Clinical Nutrition</i> , 2003, 57, 721-725.	1.3	106

#	ARTICLE	IF	CITATIONS
20	Low High-Density Lipoprotein Cholesterol. <i>Drugs</i> , 2003, 63, 1907-1945.	4.9	59
22	Role of lipid and lipoprotein profiles in risk assessment and therapy. <i>American Heart Journal</i> , 2003, 146, 227-233.	1.2	56
23	Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS). <i>American Heart Journal</i> , 2003, 146, 862-869.	1.2	69
24	Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. <i>Lancet, The</i> , 2003, 361, 777-780.	6.3	429
25	Dyslipidemia treatment: current considerations and unmet needs. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 121-134.	0.6	0
26	Body mass index, coronary heart disease and stroke in Swedish women. A prospective 19-year follow-up in the BEDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 443-450.	3.1	17
27	Lack of genetic linkage evidence for a trans-acting factor having a large effect on plasma lipoprotein[a] levels in African Americans. <i>Journal of Lipid Research</i> , 2003, 44, 1301-1305.	2.0	12
28	Triglycerides, High-Density Lipoprotein Cholesterol, and Risk of Ischemic Heart Disease: A View from the Copenhagen Male Study. <i>Metabolic Syndrome and Related Disorders</i> , 2003, 1, 33-53.	0.5	12
29	Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. <i>International Journal of Epidemiology</i> , 2003, 32, 563-572.	0.9	315
30	Apolipoproteins: the new prognostic indicator?. <i>European Heart Journal Supplements</i> , 2003, 5, D9-D16.	0.0	11
31	High lipid levels and coronary disease in women in GÅrteborgâ€”outcome and secular trends: a prospective 19 year follow-up in the BEDA study. <i>European Heart Journal</i> , 2003, 24, 704-716.	1.0	28
32	New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2470-2478.	1.8	112
33	Cardiovascular Disease in Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2003, 163, 33.	4.3	132
34	Alternative hormone replacement regimens: is there a need for further clinical trials?. <i>Current Opinion in Lipidology</i> , 2003, 14, 585-591.	1.2	11
35	Role of nonâ€”high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. <i>Current Opinion in Cardiology</i> , 2003, 18, 503-509.	0.8	20
36	Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2003, 14, 347-352.	1.2	111
37	Raising high-density lipoprotein cholesterol: where are we now?. <i>European Heart Journal Supplements</i> , 2003, 5, D17-D25.	0.0	0
39	Dietary linolenic acid is inversely associated with plasma triacylglycerol: the National Heart, Lung, and Blood Institute Family Heart Study. <i>American Journal of Clinical Nutrition</i> , 2003, 78, 1098-1102.	2.2	71

#	ARTICLE	IF	CITATIONS
40	Dyslipidemia Management in Women and Men: Exploring Potential Gender Differences. , 2004, , 234-240.		0
41	Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. American Journal of Clinical Nutrition, 2004, 79, 765-773.	2.2	158
42	Lipid and Lipoprotein Profile in Menopausal Transition. Effects of Hormones, Age and Fat Distribution. Hormone and Metabolic Research, 2004, 36, 215-220.	0.7	83
43	Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?. Journal of Infectious Diseases, 2004, 189, 1056-1074.	1.9	318
44	Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study. Clinical Chemistry, 2004, 50, 1364-1371.	1.5	107
45	Glucose-Cholesterol Interaction Magnifies Coronary Heart Disease Risk for Hypertensive Patients. Hypertension, 2004, 43, 983-987.	1.3	21
47	Association between Alcoholic Beverage Consumption and Incidence of Coronary Heart Disease in Whites and Blacks: The Atherosclerosis Risk in Communities Study. American Journal of Epidemiology, 2004, 160, 466-474.	1.6	84
48	Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 2004, 38, 253-259.	3.1	156
49	Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C*. Current Medical Research and Opinion, 2004, 20, 1253-1268.	0.9	248
50	Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA* study. Diabetic Medicine, 2004, 21, 615-622.	1.2	97
51	Do gene-environment interactions influence fasting plasma lipids? A study of twins. European Journal of Clinical Investigation, 2004, 34, 590-598.	1.7	12
52	Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. Journal of Internal Medicine, 2004, 256, 406-412.	2.7	55
53	Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 625-30.	1.3	101
54	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Current Atherosclerosis Reports, 2004, 6, 353-358.	2.0	1
55	Low-density lipoprotein particle number and risk for cardiovascular disease. Current Atherosclerosis Reports, 2004, 6, 381-387.	2.0	175
56	Deportes con alto grado de estrés físico afectan negativamente al perfil lipídico plasmático. Revista Española De Cardiología, 2004, 57, 499-506.	0.6	13
58	Sports Requiring Stressful Physical Exertion Cause Abnormalities in Plasma Lipid Profile. Revista Española De Cardiología (English Ed), 2004, 57, 499-506.	0.4	8
59	Meat-Adaptive Genes and the Evolution of Slower Aging in Humans. Quarterly Review of Biology, 2004, 79, 3-50.	0.0	188

#	ARTICLE	IF	CITATIONS
61	Role of Fibrin Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease. <i>Drugs</i> , 2004, 64, 2177-2198.	4.9	67
62	Gender-Based Differences in the Prognostic Value of Coronary Calcification. <i>Journal of Women's Health</i> , 2004, 13, 273-283.	1.5	137
63	Relation between age and gender differences in plasma triglyceride concentrations and coronary artery disease in Southern Turkey. <i>Clinica Chimica Acta</i> , 2004, 339, 123-128.	0.5	13
64	Convergent evolution in primates and an insectivore. <i>Genomics</i> , 2004, 83, 19-23.	1.3	10
65	Smoking and diabetes differ in their associations with subclinical atherosclerosis and coronary heart disease—the ARIC Study. <i>Atherosclerosis</i> , 2004, 172, 143-149.	0.4	44
66	Goals of Statin Therapy: Three Viewpoints. <i>Atherosclerosis Supplements</i> , 2004, 5, 107-114.	1.2	4
67	A dietary pattern derived to explain biomarker variation is strongly associated with the risk of coronary artery disease. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 633-640.	2.2	112
68	Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. <i>Current Opinion in Lipidology</i> , 2004, 15, 433-438.	1.2	53
69	Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK —92 Hemostasis Study. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 119-124.	0.5	19
71	Increased Triglyceride Levels in a Japanese Population Living in Southern Brazil. <i>Archives of Medical Research</i> , 2005, 36, 59-64.	1.5	3
72	Relationships Between Serum Unsaturated Fatty Acids and Coronary Risk Factors Negative Relations Between Nervonic Acid and Obesity-Related Risk Factors. <i>International Heart Journal</i> , 2005, 46, 975-985.	0.5	50
73	Evidence of age-dependent genetic influences on plasma total cholesterol. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 380-386.	3.1	5
74	The Predictive Value of Lipid Markers in Vascular Disease. <i>Current Pharmaceutical Design</i> , 2005, 11, 2209-2224.	0.9	8
75	Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women. <i>Current Pharmaceutical Design</i> , 2005, 11, 4187-4206.	0.9	5
76	Weighing in Before the Fight. <i>Circulation</i> , 2005, 112, 3368-3370.	1.6	45
78	High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. <i>European Heart Journal</i> , 2005, 26, 890-896.	1.0	187
79	The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2005, 28, 385-390.	4.3	988
80	Hormone Therapy, Lipoprotein Subclasses, and Coronary Calcification. <i>Archives of Internal Medicine</i> , 2005, 165, 510.	4.3	44

#	ARTICLE	IF	CITATIONS
81	Fat, Fit, and Leading the Charge. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2013-2015.	1.1	4
82	A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. <i>Journal of Lipid Research</i> , 2005, 46, 2015-2022.	2.0	88
83	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Archives of Internal Medicine</i> , 2005, 165, 2479.	4.3	244
84	Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. <i>European Heart Journal</i> , 2005, 26, 271-278.	1.0	124
85	Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. <i>Country Review Ukraine</i> , 2005, 7, F56-F62.	0.8	12
87	Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 326.	3.8	639
88	Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2005, 183, 301-307.	0.4	139
89	Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1003-1012.	1.2	136
91	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. <i>Current Medical Research and Opinion</i> , 2005, 21, 299-305.	0.9	23
92	Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients. <i>International Journal of STD and AIDS</i> , 2005, 16, 365-369.	0.5	8
93	Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. <i>International Journal of Cardiology</i> , 2005, 101, 435-440.	0.8	35
94	Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2005, 102, 477-485.	0.8	25
95	Rheumatoid disease and ischaemic heart disease: Insights from pathophysiology and vascular biology. <i>International Journal of Cardiology</i> , 2005, 105, 1-10.	0.8	16
96	Perspectives on Dyslipidemia and Coronary Heart Disease in Women. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1628-1635.	1.2	67
97	Risk Factors for Atherosclerotic Vascular Disease. <i>Handbook of Experimental Pharmacology</i> , 2005, , 71-105.	0.9	21
98	Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control. <i>Current Medical Research and Opinion</i> , 2006, 22, S15-S26.	0.9	9
99	The potential for CETP inhibition to reduce cardiovascular disease risk. <i>Current Medical Research and Opinion</i> , 2006, 22, 2467-2478.	0.9	10
100	LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. <i>Atherosclerosis</i> , 2006, 186, 1-11.	0.4	43

#	ARTICLE	IF	CITATIONS
101	Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. <i>Atherosclerosis</i> , 2006, 189, 364-368.	0.4	36
102	CETP levels rather than polymorphisms as markers of coronary risk: Healthy athlete with high HDL-C and coronary disease—effectiveness of probucol. <i>Atherosclerosis</i> , 2006, 186, 225-227.	0.4	3
103	Elevated Lipoprotein(a)—A Genetic Risk Factor for Premature Vascular Disease in People With and Without Standard Risk Factors: A Review. <i>Disease-a-Month</i> , 2006, 52, 5-50.	0.4	56
104	Gender differences in correlations among cardiovascular risk factors. <i>Gender Medicine</i> , 2006, 3, 196-205.	1.4	14
105	Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1473-1477.	0.5	78
106	Apolipoprotein A1 and B. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 733-750.	0.7	44
107	The Relative Strength of C-Reactive Protein and Lipid Levels as Determinants of Ischemic Stroke Compared With Coronary Heart Disease in Women. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2235-2242.	1.2	109
108	Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 571-577.	3.1	106
109	Proteomic Study of Plasma from Moderate Hypercholesterolemic Patients. <i>Journal of Proteome Research</i> , 2006, 5, 2301-2308.	1.8	40
110	Fatty acids bound to human serum albumin and its structural variants modulate apolipoprotein B secretion in HepG2 cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 717-724.	1.2	6
111	Effects of synthetic progestagens on autonomic tone, neurohormones and C-reactive protein levels in young healthy females in reproductive age. <i>International Journal of Cardiology</i> , 2006, 111, 42-48.	0.8	16
113	Níveis plasmáticos elevados de lipoproteína(a) correlacionados com a gravidade da doença arterial coronariana em pacientes submetidos à angiografia. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, 260-266.	0.3	7
114	Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1363.	3.8	183
115	Intake of a Single Morning Dose of Standard and Novel Plant Sterol Preparations for 4 Weeks Does Not Dramatically Affect Plasma Lipid Concentrations in Humans. <i>Journal of Nutrition</i> , 2006, 136, 1012-1016.	1.3	50
116	Palm and partially hydrogenated soybean oils adversely alter lipoprotein profiles compared with soybean and canola oils in moderately hyperlipidemic subjects. <i>American Journal of Clinical Nutrition</i> , 2006, 84, 54-62.	2.2	135
117	Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. <i>Journal of Internal Medicine</i> , 2006, 259, 247-258.	2.7	405
118	The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. <i>Journal of Internal Medicine</i> , 2006, 259, 493-519.	2.7	457
119	Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. <i>Journal of Internal Medicine</i> , 2006, 259, 481-492.	2.7	219

#	ARTICLE	IF	CITATIONS
120	A randomized controlled trial of dietary fiber intake on serum lipids. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 62-68.	1.3	80
121	Apolipoprotein A-I and risk for cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , 2006, 8, 365-373.	2.0	22
122	Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. , 2006, 111, 893-908.		113
123	HDL and the progression of atherosclerosis: new insights. <i>Country Review Ukraine</i> , 2006, 8, F4-F9.	0.8	10
124	Apolipoprotein E Polymorphisms Predict Low Density Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary Heart Disease in 12,491 ARIC Study Participants. <i>American Journal of Epidemiology</i> , 2006, 164, 342-348.	1.6	116
125	Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 184-188.	0.5	180
126	Serious Gaps: How the Lack of Sex/Gender-Based Research Impairs Health. <i>Journal of Women's Health</i> , 2006, 15, 1116-1122.	1.5	41
127	The ratio of apoB/apoA1, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1015-21.	1.4	41
128	Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis. <i>Pharmacological Reviews</i> , 2006, 58, 342-374.	7.1	629
129	Diabetes, but not the metabolic syndrome, predicts the severity and extent of coronary artery disease in women. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 100, 575-581.	0.2	27
130	Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. <i>Cardiovascular Research</i> , 2007, 75, 566-574.	1.8	18
131	Lipid levels and the risk of ischemic stroke in women. <i>Neurology</i> , 2007, 68, 556-562.	1.5	191
132	Significance of Determining Levels of Apolipoproteins A-I and B in the Diagnostics and Assessment of Lipid-Related Atherogenic Risk in Hyperalpha-Lipoproteinemia, Hypocholesterolemia and Hypo-Hdl-Cholesterolemia. <i>Journal of Medical Biochemistry</i> , 2007, 26, 206-214.	0.7	0
133	Triglycerides and the Risk of Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 450-458.	1.6	1,216
134	Cholesteryl Ester Transfer Protein (CETP) Expression Protects Against Diet Induced Atherosclerosis in SR-BI Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 858-864.	1.1	57
135	Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study. <i>Climacteric</i> , 2007, 10, 225-237.	1.1	13
136	High-Density Lipoprotein as a Therapeutic Target. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 786.	3.8	415
137	Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men. <i>Annals of Internal Medicine</i> , 2007, 147, 377.	2.0	130

#	ARTICLE	IF	CITATIONS
138	Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 776.	3.8	496
140	A comprehensive view of sex-specific issues related to cardiovascular disease. <i>Cmaj</i> , 2007, 176, S1-S44.	0.9	348
141	Comparison of demography, diet, lifestyle, and serum lipid levels between the Guangxi Bai Ku Yao and Han populations. <i>Journal of Lipid Research</i> , 2007, 48, 2673-2681.	2.0	70
142	Role of the Apolipoprotein Bâ€“Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Caseâ€“Control Analysis in EPIC-Norfolk. <i>Annals of Internal Medicine</i> , 2007, 146, 640.	2.0	140
143	Sources Of Variability Of Plasma HDL-Cholesterol Levels. <i>Future Lipidology</i> , 2007, 2, 557-569.	0.5	3
144	Cardiovascular risks in spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 358-362.	2.0	78
145	Trends in ATP-III-Defined High Blood Cholesterol Prevalence, Awareness, Treatment and Control Among U.S. Adults. <i>Annals of Epidemiology</i> , 2007, 17, 548-555.	0.9	112
146	Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. <i>Clinical Therapeutics</i> , 2007, 29, 196-209.	1.1	11
147	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , 2007, 9, 81-88.	2.0	10
148	HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2007, 357, 1301-1310.	13.9	1,390
149	The Effect of Wet Cupping on Serum Lipid Concentrations of Clinically Healthy Young Men: A Randomized Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2007, 13, 79-82.	2.1	56
150	Lipoprotein (a) and risk of ischemic stroke in young adults. <i>Journal of the Neurological Sciences</i> , 2007, 252, 39-44.	0.3	24
151	Assessing the clinical utility of biomarkers in medicine. <i>Biomarkers in Medicine</i> , 2007, 1, 419-436.	0.6	37
152	Cholesterol ester transfer protein (CETP) and atherosclerosis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 137-145.	0.5	4
153	High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?. <i>Journal of Clinical Lipidology</i> , 2007, 1, 57-64.	0.6	10
154	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. <i>Vascular Health and Risk Management</i> , 2007, Volume 3, 467-479.	1.0	17
155	Primary Prevention of Ischemic Heart Disease. , 2007, , 178-220.		1
157	Common carotid artery wall thickness and external diameter as predictors of prevalent and incident cardiac events in a large population study. <i>Cardiovascular Ultrasound</i> , 2007, 5, 11.	0.5	60

#	ARTICLE	IF	CITATIONS
158	Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. <i>International Journal of Obesity</i> , 2007, 31, 791-796.	1.6	74
159	Identifying obese women most at risk from cardiovascular disease. <i>International Journal of Obesity</i> , 2007, 31, S19-S25.	1.6	3
160	HDL-c is a powerful lipid predictor of cardiovascular diseases. <i>International Journal of Clinical Practice</i> , 2007, 61, 1905-1913.	0.8	50
161	Predictors of Aortoâ€“Saphenous Vein Bypass Narrowing Late After Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2007, 100, 640-645.	0.7	27
162	A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis. <i>European Journal of Clinical Investigation</i> , 2007, 37, 249-256.	1.7	7
163	Nine months aerobic fitness induced changes on blood lipids and lipoproteins in untrained subjects versus controls. <i>European Journal of Applied Physiology</i> , 2007, 99, 291-299.	1.2	34
164	Changes in Plasma LDL and HDL Composition in Patients Undergoing Cardiac Surgery. <i>Lipids</i> , 2007, 42, 1143-1153.	0.7	14
165	Perspectives and current strategies for dyslipidemia in women. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 159-166.	0.8	0
166	Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach. <i>Clinical Biochemistry</i> , 2007, 40, 1000-1006.	0.8	22
167	Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. <i>Clinical Biochemistry</i> , 2007, 40, 1180-1187.	0.8	3
168	Triglycerides and risk for coronary artery disease. <i>Current Atherosclerosis Reports</i> , 2008, 10, 386-390.	2.0	92
169	When high is low: Raising low levels of high-density lipoprotein cholesterol. <i>Current Cardiology Reports</i> , 2008, 10, 488-496.	1.3	13
170	Interactions between alcohol intake and the polymorphism of rs708272 on serum high-density lipoprotein cholesterol levels in the Guangxi Hei Yi Zhuang population. <i>Alcohol</i> , 2008, 42, 583-591.	0.8	27
171	The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 271-278.	2.2	66
172	Apolipoproteins B and AI and the risk of ischemic cerebrovascular events in patients with pre-existing atherothrombotic disease. <i>Journal of the Neurological Sciences</i> , 2008, 270, 82-87.	0.3	16
173	HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Translational Research</i> , 2008, 152, 3-10.	2.2	61
174	High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2008, 51, 634-642.	1.2	330
175	Lipoprotein Management in Patients With Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1512-1524.	1.2	466

#	ARTICLE	IF	CITATIONS
176	Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients. <i>Journal of the American College of Cardiology</i> , 2008, 52, 633-635.	1.2	4
177	Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. <i>Journal of Clinical Lipidology</i> , 2008, 2, 343-353.	0.6	7
178	Diabetic dyslipidemia and the metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2008, 2, 208-222.	1.8	6
179	Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2008, 10, 213.	1.6	94
180	An Italian Chart for Cardiovascular Risk Estimate Including High-Density Lipoprotein-Cholesterol. <i>Disease Management and Health Outcomes</i> , 2008, 16, 183-197.	0.3	2
181	Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. <i>Journal of Chiropractic Medicine</i> , 2008, 7, 48-58.	0.3	92
182	Association of serum lipid indices with large artery atherosclerotic stroke. <i>Neurology</i> , 2008, 70, 841-847.	1.5	50
183	Apolipoprotein B/A1 and risk of cardiovascular disease. <i>Lancet, The</i> , 2008, 372, 185-186.	6.3	12
184	Chapter 8 Atherogenic Lipoprotein Subprofiling. <i>Advances in Clinical Chemistry</i> , 2008, , 295-317.	1.8	10
185	Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. <i>Current Medical Research and Opinion</i> , 2008, 24, 2815-2820.	0.9	5
186	Origins of intestinal ABCA1-mediated HDL-cholesterol. <i>Journal of Lipid Research</i> , 2008, 49, 2605-2619.	2.0	38
187	BMI, lipid profile, physical fitness and smoking habits of young male adults and the association with parental education. <i>European Journal of Public Health</i> , 2008, 19, 46-51.	0.1	15
188	Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease_{title}>Large-Scale Prospective Data</sub>. <i>Archives of Internal Medicine</i> , 2008, 168, 598.	4.3	231
189	Association of TaqIB Polymorphism in the Cholesteryl Ester Transfer Protein Gene With Serum Lipid Levels in the Guangxi Hei Yi Zhuang and Han Populations. <i>Journal of Investigative Medicine</i> , 2008, 56, 847-857.	0.7	7
190	A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 470-476.	1.8	152
191	Lipoprotein Management in Patients With Cardiometabolic Risk. <i>Diabetes Care</i> , 2008, 31, 811-822.	4.3	536
193	Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. <i>Journal of Biological Chemistry</i> , 2008, 283, 11633-11644.	1.6	72
194	Reducing lipids for CV protection in CKD patientsâ€”current evidence. <i>Kidney International</i> , 2008, 74, S24-S28.	2.6	15

#	ARTICLE	IF	CITATIONS
195	Association between Protein Bound Sialic Acid and High Sensitivity C-Reactive Protein in Prehypertension: A Possible Indication of Underlying Cardiovascular Risk. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 367-374.	0.5	15
197	HDL-cholesterol modulation and its impact on the management of cardiovascular risk. <i>Annals of Clinical Biochemistry</i> , 2008, 45, 122-128.	0.8	9
198	Pentanucleotide Repeat Polymorphism, Lipoprotein(a) Levels, and Risk of Ischemic Heart Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3769-3776.	1.8	21
199	Cardiovascular disease prevention tailored for women. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1123-1134.	0.6	13
200	Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. <i>Current Medical Research and Opinion</i> , 2008, 24, 2711-2717.	0.9	23
201	Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2097-2103.	1.8	28
202	Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. <i>Heart</i> , 2008, 94, 706-714.	1.2	106
203	Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels. <i>British Journal of Nutrition</i> , 2008, 99, 1083-1088.	1.2	49
204	Newer Markers for Population Screening: Focus on Lipoprotein-Related Markers. , 0, , 181-203.		0
205	Maximal Physiological Responses between Aquatic and Land Exercise in Overweight Women. <i>Medicine and Science in Sports and Exercise</i> , 2008, 40, 959-964.	0.2	26
206	Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 142-146.	1.2	15
207	Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. <i>Current Opinion in Lipidology</i> , 2008, 19, 585-591.	1.2	2
209	The independent relationship between triglycerides and coronary heart disease. <i>Vascular Health and Risk Management</i> , 2008, , 89.	1.0	33
210	Therapies to Increase High-Density Lipoprotein Cholesterol and Their Effect on Cardiovascular Outcomes and Regression of Atherosclerosis. <i>American Journal of the Medical Sciences</i> , 2008, 336, 64-68.	0.4	10
211	Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. <i>Vascular Health and Risk Management</i> , 2009, 5, 801.	1.0	15
212	Lipid Measures and Cardiovascular Disease Prediction. <i>Disease Markers</i> , 2009, 26, 209-216.	0.6	11
213	Poor Glycemic Control Is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1550-1552.	4.3	41
214	Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 341-347.	1.1	95

#	ARTICLE	IF	CITATIONS
215	Hyperlipidaemia and its risk factors in the Guangxi Bai Ku Yao and Han populations. <i>Public Health Nutrition</i> , 2009, 12, 816-824.	1.1	25
216	Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use. <i>Circulation</i> , 2009, 119, 2396-2404.	1.6	77
217	Towards companion diagnostics for the management of statin therapy. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 659-671.	1.6	0
218	Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels. <i>Current Medicinal Chemistry</i> , 2009, 16, 144-156.	1.2	9
219	The emerging role of high-density lipoprotein cholesterol in hypertension trials. <i>Journal of Hypertension</i> , 2009, 27, 458-460.	0.3	3
220	Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 412.	3.8	1,279
221	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 404-423.	3.1	48
222	Ten-Year Survival in 75-Year-Old Men and Women: Predictive Ability of Total Cholesterol, HDL-C, and LDL-C. <i>Current Gerontology and Geriatrics Research</i> , 2009, 2009, 1-7.	1.6	18
223	VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. <i>Journal of Lipid Research</i> , 2009, 50, 376-385.	2.0	69
224	Clinical impact of dyslipidemia for coronary plaque vulnerability in acute coronary syndrome without metabolic syndrome. <i>Journal of Cardiology</i> , 2009, 54, 394-401.	0.8	5
225	Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1324-1330.	6.7	101
226	Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids. <i>Current Atherosclerosis Reports</i> , 2009, 11, 71-79.	2.0	32
227	Effects of inflammation on cholesterol metabolism: Impact on systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009, 11, 255-260.	2.1	23
228	Clinical features of early recurrent myocardial infarction. <i>Heart and Vessels</i> , 2009, 24, 347-351.	0.5	7
229	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. <i>Clinical Endocrinology</i> , 2009, 70, 815-828.	1.2	69
230	Reversal of Small, Dense LDL Subclass Phenotype by Normalization of Adiposity. <i>Obesity</i> , 2009, 17, 1768-1775.	1.5	36
231	Low density lipoprotein receptor polymorphisms and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 496-498.	1.9	8
232	Fractionation of human serum lipoproteins and simultaneous enzymatic determination of cholesterol and triglycerides. <i>Analytica Chimica Acta</i> , 2009, 654, 85-91.	2.6	32

#	ARTICLE	IF	CITATIONS
233	Is a history of gestational diabetes related to risk factors for coronary heart disease?. Research in Nursing and Health, 2009, 32, 298-306.	0.8	6
234	Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated?. Clinical Cardiology, 2009, 32, 482-486.	0.7	72
235	Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clinical Chemistry, 2009, 55, 407-419.	1.5	277
236	Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation, 2009, 119, 931-939.	1.6	427
237	Apolipoproteins and long-term prognosis in coronary heart disease patients. American Heart Journal, 2009, 157, 103-110.	1.2	14
238	Metabolic syndrome: A review of emerging markers and management. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2009, 3, 240-254.	1.8	15
239	Effect of Sophora japonica Extract on Lipid Content in High Fat Diet Fed Rats. Journal of the Korean Society for Applied Biological Chemistry, 2009, 52, 133-138.	0.9	0
240	Interventional Treatment of Advanced Ischemic Heart Disease. , 2009, , .		0
241	Effects of isoflavone-supplemented soy yogurt on lipid parameters and atherosclerosis development in hypercholesterolemic rabbits: a randomized double-blind study. Lipids in Health and Disease, 2009, 8, 40.	1.2	25
242	Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis, 2009, 204, 208-215.	0.4	74
243	HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis, 2009, 206, 611-616.	0.4	193
244	Advanced Lipoprotein Testing: Recommendations Based on Current Evidence. Endocrinology and Metabolism Clinics of North America, 2009, 38, 1-31.	1.2	19
245	Novel Therapies for Increasing Serum Levels of HDL. Endocrinology and Metabolism Clinics of North America, 2009, 38, 151-170.	1.2	9
246	Lipoprotein a: where are we now?. Current Opinion in Cardiology, 2009, 24, 351-357.	0.8	52
247	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. Current Pharmaceutical Design, 2009, 15, 1054-1062.	0.9	21
248	Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2009, 151, 496.	2.0	305
249	Polymorphism of the Sterol Regulatory Element-Binding Protein-2 Gene and Its Association With Serum Lipid Levels in the Guangxi Hei Yi Zhuang and Han Populations. American Journal of the Medical Sciences, 2009, 337, 14-22.	0.4	9
250	Understanding Stroke in Women. Stroke, 2009, 40, 674-675.	1.0	6

#	ARTICLE	IF	CITATIONS
251	Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome. Current Pharmaceutical Design, 2009, 15, 3446-3462.	0.9	7
252	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. Current Drug Targets, 2009, 10, 320-327.	1.0	27
253	Nonfasting Hyperlipidemia and Cardiovascular Disease. Current Drug Targets, 2009, 10, 328-335.	1.0	85
254	High-Density Lipoprotein-Raising Strategies: Update 2010. Current Pharmaceutical Design, 2010, 16, 1517-1530.	0.9	14
255	High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease. Current Pharmaceutical Design, 2010, 16, 1480-1493.	0.9	52
256	Lipoprotein subfractions and cardiovascular disease risk. Current Opinion in Lipidology, 2010, 21, 305-311.	1.2	216
257	Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 556-561.	3.1	2
258	Loneliness and the metabolic syndrome in a population-based sample of middle-aged and older adults.. Health Psychology, 2010, 29, 550-554.	1.3	95
259	Gender determinants of cardiovascular risk factors and diseases. Journal of Cardiovascular Medicine, 2010, 11, 207-220.	0.6	82
260	Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. Clinical Lipidology, 2010, 5, 527-541.	0.4	2
261	Associations Between Lipid Measures and Metabolic Syndrome, Insulin Resistance and Adiponectin - Usefulness of Lipid Ratios in Korean Men and Women -. Circulation Journal, 2010, 74, 931-937.	0.7	84
262	Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatology International, 2010, 30, 1411-1416.	1.5	27
263	Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clinical Research in Cardiology, 2010, 99, 723-733.	1.5	38
264	Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention. Lipids, 2010, 45, 907-914.	0.7	251
265	Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found. Current Atherosclerosis Reports, 2010, 12, 331-335.	2.0	3
266	Recognizing and Improving Health Care Disparities in the Prevention of Cardiovascular Disease in Women. Current Cardiology Reports, 2010, 12, 488-496.	1.3	43
267	Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. , 2010, 126, 314-345.		196
268	Perímetro do abdômen é o melhor indicador antropométrico de riscos para doenças cardiovasculares. Revista Brasileira De Cineantropometria E Desempenho Humano, 2010, , 1-7.	0.5	2

#	ARTICLE	IF	CITATIONS
269	Dyslipidemia Management in Women and Men. , 2010, , 175-185.		0
270	Relative Contribution of Lipids and Apolipoproteins to Incident Coronary Heart Disease and Ischemic Stroke: The PRIME Study. <i>Cerebrovascular Diseases</i> , 2010, 30, 252-259.	0.8	52
271	TNF- α decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2. <i>Journal of Lipid Research</i> , 2010, 51, 1407-1415.	2.0	62
272	Biochemical characterization of cholesteryl ester transfer protein inhibitors. <i>Journal of Lipid Research</i> , 2010, 51, 2739-2752.	2.0	92
273	Increased Stroke Risk and Lipoprotein(a) in a Multiethnic Community: The Northern Manhattan Stroke Study. <i>Cerebrovascular Diseases</i> , 2010, 30, 237-243.	0.8	27
274	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. <i>European Heart Journal</i> , 2010, 31, 149-164.	1.0	256
275	Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. <i>Current Medical Research and Opinion</i> , 2010, 26, 2833-2839.	0.9	13
276	Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. <i>Current Medical Research and Opinion</i> , 2010, 26, 365-375.	0.9	13
277	Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease. <i>European Journal of Heart Failure</i> , 2010, 12, 254-259.	2.9	6
278	Association of Scavenger Receptor Class B Type I Polymorphisms With Subclinical Atherosclerosis. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 47-52.	5.1	44
279	The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment. <i>Cardiology</i> , 2010, 117, 96-104.	0.6	2
280	Translating genomic analyses into improved management of coronary artery disease. <i>Future Cardiology</i> , 2010, 6, 507-521.	0.5	6
282	High-Density Lipoprotein and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1283-1299.	1.2	190
283	Carotid Ultrasound, Coronary Calcium, and Dyslipidemia Patterns in the MESA (Multi-Ethnic Study of) Tj ETQq1 1 0,784314 rgBT /Overlo 1.2 2		
284	High-density lipoproteins: Marker of cardiovascular risk and therapeutic target. <i>Journal of Clinical Lipidology</i> , 2010, 4, 359-364.	0.6	29
285	Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. <i>Journal of Clinical Lipidology</i> , 2010, 4, 365-370.	0.6	14
286	Plasma folate levels are associated with the lipoprotein profile: a retrospective database analysis. <i>Nutrition Journal</i> , 2010, 9, 31.	1.5	25
287	Frequent Cholesterol Intake Up-regulates Intestinal NPC1L1, ACAT2, and MTP. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 5851-5857.	2.4	9

#	ARTICLE	IF	CITATIONS
288	Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. <i>Clinica Chimica Acta</i> , 2010, 411, 1774-1780.	0.5	42
289	Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: The Suita study. <i>Atherosclerosis</i> , 2010, 209, 290-294.	0.4	33
290	Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. <i>Atherosclerosis</i> , 2010, 209, 579-584.	0.4	17
291	Lipoprotein(a) and ischemic heart disease—A causal association? A review. <i>Atherosclerosis</i> , 2010, 211, 15-23.	0.4	92
293	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet</i> , The, 2010, 376, 333-339.	6.3	221
294	Genetic causes of high and low serum HDL-cholesterol. <i>Journal of Lipid Research</i> , 2010, 51, 2032-2057.	2.0	172
295	Effect of Niacin Therapy on Cardiovascular Outcomes in Patients With Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 158-166.	1.0	56
296	The characteristics of dyslipidemia patients with different durations in Beijing: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2010, 9, 115.	1.2	3
297	Association between CETP Taq1B and LIPC -514C/T polymorphisms with the serum lipid levels in a group of Tehran's population: a cross sectional study. <i>Lipids in Health and Disease</i> , 2010, 9, 96.	1.2	26
298	Quinazolin-4(3H)-ones capable of upregulating the expression of endogenous apolipoprotein A-1. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 431-435.	2.4	0
299	The Correlation between Lipids Ratio and Degree of Coronary Artery Stenosis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 53-56.	1.0	21
300	Prediction of Cardiovascular Disease Events. <i>Cardiology Clinics</i> , 2011, 29, 1-13.	0.9	10
301	Opening a New Lipid "Apo-theatry": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. <i>Mayo Clinic Proceedings</i> , 2011, 86, 762-780.	1.4	32
302	The REALIST (REsiduAl risk, Lipids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. <i>Endocrinología y Nutrición (English)</i> Tj ETQq1 1 0.784310.9BT /Overlock 10T	0.7	10
304	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. <i>Nature Reviews Cardiology</i> , 2011, 8, 253-265.	6.1	90
305	Determination of cholesterol and triglycerides in serum lipoproteins using flow field-flow fractionation coupled to gas chromatography—mass spectrometry. <i>Analytica Chimica Acta</i> , 2011, 706, 361-366.	2.6	12
306	The relation between serum visfatin levels and cardiovascular involvement in rheumatoid arthritis. <i>Alexandria Journal of Medicine</i> , 2011, 47, 117-124.	0.4	1
307	Interactions of the LIPC 584C>T polymorphism and alcohol consumption on serum lipid levels. <i>Alcohol</i> , 2011, 45, 681-687.	0.8	14

#	ARTICLE	IF	CITATIONS
308	Gender differences in the association between smoking and dyslipidemia: 2005 Korean National Health and Nutrition Examination Survey. <i>Clinica Chimica Acta</i> , 2011, 412, 1600-1605.	0.5	29
309	Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. <i>International Journal of Cardiology</i> , 2011, 150, 17-21.	0.8	53
310	The role of HDL cholesterol in metabolic syndrome predicting cardiovascular events. The Gubbio population study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 315-322.	1.1	17
312	Introduction. <i>Atherosclerosis Supplements</i> , 2011, 12, 265-266.	1.2	8
313	HDL-C: Role as a risk modifier. <i>Atherosclerosis Supplements</i> , 2011, 12, 267-270.	1.2	87
314	Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain. DYSIS-Spain Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 286-294.	0.4	22
315	Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. <i>Atherosclerosis</i> , 2011, 214, 196-202.	0.4	81
317	Apolipoprotein B is Highly Associated with the Risk of Coronary Heart Disease as Estimated by the Framingham Risk Score in Healthy Korean Men. <i>Journal of Korean Medical Science</i> , 2011, 26, 631.	1.1	10
318	Housefly Maggots (<i>Musca domestica</i>) Protein-enriched Fraction/ extracts (PE) Inhibit Lipopolysaccharide-induced Atherosclerosis Pro-inflammatory Responses. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 282-290.	0.9	33
319	The effect of the addition of resistance training to a dietary education intervention on apolipoproteins and diet quality in overweight and obese older adults. <i>Clinical Interventions in Aging</i> , 2011, 6, 235.	1.3	29
320	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. <i>Drug Design, Development and Therapy</i> , 2011, 5, 325.	2.0	201
321	Single-Nucleotide Polymorphisms in LPA Explain Most of the Ancestry-Specific Variation in Lp(a) Levels in African Americans. <i>PLoS ONE</i> , 2011, 6, e14581.	1.1	60
322	Variation in LPA Is Associated with Lp(a) Levels in Three Populations from the Third National Health and Nutrition Examination Survey. <i>PLoS ONE</i> , 2011, 6, e16604.	1.1	34
323	Association of High-Density Lipoprotein Cholesterol With Coronary Heart Disease Risk Across Categories of Low-Density Lipoprotein Cholesterol: The Atherosclerosis Risk in Communities Study. <i>American Journal of the Medical Sciences</i> , 2011, 341, 173-180.	0.4	15
324	Affective Response And Pain Measurement Correlations In A 500 Mile Pilgrimage: El Camino De Santiago. <i>Medicine and Science in Sports and Exercise</i> , 2011, 43, 521.	0.2	0
325	The Effect of SEX/Gender on Cardiovascular Pharmacology. <i>Current Pharmaceutical Design</i> , 2011, 17, 1095-1107.	0.9	33
326	Anacetrapib: A New Weapon Against Dyslipidemia. <i>Current Clinical Pharmacology</i> , 2011, 6, 227-235.	0.2	1
327	Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 1082-1089.	0.9	20

#	ARTICLE	IF	CITATIONS
328	Structural and biophysical insight into cholesteryl ester-transfer protein. <i>Biochemical Society Transactions</i> , 2011, 39, 1000-1005.	1.6	11
330	Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels. <i>Annals of Internal Medicine</i> , 2011, 155, 742.	2.0	52
331	Comparison of High-Density Lipoprotein Cholesterol to Apolipoprotein A-I and A-II to Predict Coronary Calcium and the Effect of Insulin Resistance. <i>American Journal of Cardiology</i> , 2011, 107, 393-398.	0.7	16
332	Comparisons of Apolipoprotein B Levels Estimated by Immunoassay, Nuclear Magnetic Resonance, Vertical Auto Profile, and Non-High-Density Lipoprotein Cholesterol in Subjects With Hypertriglyceridemia (SAFARI Trial). <i>American Journal of Cardiology</i> , 2011, 108, 40-46.	0.7	29
333	Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. <i>American Journal of Cardiology</i> , 2011, 108, 3B-24B.	0.7	254
334	Novel Biomarkers and Subclinical Atherosclerosis. , 2011, , 461-486.		0
335	What intervention trials donâ€™t tell us: the residual risk in primary prevention. <i>Internal and Emergency Medicine</i> , 2011, 6, 53-60.	1.0	2
336	Experimental Models for the Investigation of High-Density Lipoproteinâ€“Mediated Cholesterol Efflux. <i>Current Atherosclerosis Reports</i> , 2011, 13, 266-276.	2.0	45
337	The Incremental Value of Lipids and Inflammatory Biomarkers in Determining Residual Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2011, 13, 373-380.	2.0	13
338	CETP Inhibition: Does the Future Look Promising?. <i>Current Cardiology Reports</i> , 2011, 13, 559-565.	1.3	8
339	Diet and serum lipids: changes over socio-economic transition period in Lithuanian rural population. <i>BMC Public Health</i> , 2011, 11, 447.	1.2	31
340	Characteristics of High-density Lipoprotein Subclasses Distribution for Subjects with Desirable Total Cholesterol Levels. <i>Lipids in Health and Disease</i> , 2011, 10, 64.	1.2	5
341	Synthesis and antidyslipidemic activity of chalcone fibrates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3475-3478.	1.0	17
342	Upright water-based exercise to improve cardiovascular and metabolic health: A qualitative review. <i>Complementary Therapies in Medicine</i> , 2011, 19, 93-103.	1.3	72
343	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. <i>Clinical Lipidology</i> , 2011, 6, 181-208.	0.4	9
344	Update on therapies targeting HDL. <i>Current Opinion in Lipidology</i> , 2011, 22, 514-516.	1.2	1
345	Hyperlipidemia in Primary Care. , 2011, , .		2
346	Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice. <i>Current Pharmaceutical Design</i> , 2011, 17, 4132-4146.	0.9	47

#	ARTICLE	IF	CITATIONS
347	Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. <i>Hypertension Research</i> , 2011, 34, 489-495.	1.5	21
348	Mining the LIPG Allelic Spectrum Reveals the Contribution of Rare and Common Regulatory Variants to HDL Cholesterol. <i>PLoS Genetics</i> , 2011, 7, e1002393.	1.5	32
349	Trends Related to Aging and Co-Occurring Disorders in HIV-Infected Drug Users. <i>Substance Use and Misuse</i> , 2011, 46, 233-244.	0.7	10
350	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. <i>European Heart Journal</i> , 2012, 33, 857-865.	1.0	201
351	Serum Lipid Profile of Newly Diagnosed Hypertensive Patients in Nnewi, South-East Nigeria. <i>International Journal of Hypertension</i> , 2012, 2012, 1-7.	0.5	31
352	ELISA System for Human Endothelial Lipase. <i>Clinical Chemistry</i> , 2012, 58, 1656-1664.	1.5	17
353	Lipid Effects of Peroxisome Proliferator-Activated Receptor- β Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2289-2294.	1.1	63
354	Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects. <i>Circulation</i> , 2012, 125, 241-249.	1.6	239
355	Lipoprotein(a), Ethnicity, and Cardiovascular Risk. <i>Circulation</i> , 2012, 125, 207-209.	1.6	4
356	Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. <i>Annals of Medicine</i> , 2012, 44, 262-270.	1.5	26
357	Chitooligosaccharides decreases plasma lipid levels in healthy men. <i>International Journal of Food Sciences and Nutrition</i> , 2012, 63, 103-106.	1.3	47
358	Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration. <i>Epigenomics</i> , 2012, 4, 623-639.	1.0	44
359	Apolipoprotein E Gene Polymorphisms Are Strong Predictors of Inflammation and Dyslipidemia in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 218-225.	1.0	26
360	Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort. <i>Journal of Lipid Research</i> , 2012, 53, 266-272.	2.0	20
361	Possible Modulation of Glycated Protein Levels in Prehypertension by Lipid Peroxides. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 517-522.	0.5	3
362	Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2839-2847.	0.4	40
363	Torcetrapib impairs endothelial function in hypertension. <i>European Heart Journal</i> , 2012, 33, 1615-1624.	1.0	75
364	HDL-Related Mechanisms of Olive Oil Protection in Cardiovascular Disease. <i>Current Vascular Pharmacology</i> , 2012, 10, 392-409.	0.8	16

#	ARTICLE	IF	CITATIONS
365	Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits. Current Pharmaceutical Biotechnology, 2012, 13, 27-36.	0.9	1
366	Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications. Clinical Lipidology, 2012, 7, 455-469.	0.4	1
367	Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 1-17.	2.7	16
368	Sexual dimorphism of abdominal aortic aneurysms: A striking example of "male disadvantage" in cardiovascular disease. Atherosclerosis, 2012, 225, 22-28.	0.4	24
369	High-density lipoprotein subclasses and their relationship to cardiovascular disease. Journal of Clinical Lipidology, 2012, 6, 496-523.	0.6	112
370	Low Levels of High-Density Lipoproteins Cholesterol Are Independently Associated With Acute Coronary Heart Disease in Patients Hospitalized for Chest Pain. Revista Espanola De Cardiologia (English Ed), 2012, 65, 319-325.	0.4	24
371	High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities. Revista Espanola De Cardiologia (English Ed), 2012, 65, 305-308.	0.4	9
372	Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology, 2012, 60, 2372-2379.	1.2	172
374	Extended-release niacin with laropirant: a review on efficacy, clinical effectiveness and safety. Expert Opinion on Pharmacotherapy, 2012, 13, 1345-1362.	0.9	24
375	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice, 2012, 18, 1-78.	1.1	386
376	Apolipoprotein C-II as a Potential Modulator of the Association Between HDL Cholesterol and Incident Coronary Heart Disease. Journal of the American Heart Association, 2012, 1, .	1.6	115
377	Effect of soy and milk protein supplementation on serum lipid levels: a randomized controlled trial. European Journal of Clinical Nutrition, 2012, 66, 419-425.	1.3	24
378	Predicting disease by using data mining based on healthcare information system. , 2012, , .		37
379	Las concentraciones bajas de colesterol unido a las lipoproteínas de alta densidad se asocian de manera independiente a enfermedad coronaria aguda en pacientes que ingresan por dolor torácico. Revista Espanola De Cardiologia, 2012, 65, 319-325.	0.6	33
380	Lipoproteínas de alta densidad y reducción de riesgo cardiovascular: ¿promesas o realidades?. Revista Espanola De Cardiologia, 2012, 65, 305-308.	0.6	12
381	Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study. American Heart Journal, 2012, 163, 515-521.e3.	1.2	51
382	Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 433-439.	0.7	32
383	Association between Lipoprotein (a) level on admission and the incidence of subsequent cardiovascular events in patients with acute coronary syndrome. International Journal of Cardiology, 2012, 158, 464-466.	0.8	12

#	ARTICLE	IF	CITATIONS
384	Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 490-501.	1.2	75
385	Oxidized low-density lipoproteins and their antibodies: Relationships with the reverse cholesterol transport and carotid atherosclerosis in adults without cardiovascular diseases. <i>Clinica Chimica Acta</i> , 2012, 413, 1472-1478.	0.5	5
386	Combined estrogen and progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. <i>Pathophysiology</i> , 2012, 19, 29-34.	1.0	16
387	High hydrostatic pressure extract of garlic increases the HDL cholesterol level via up-regulation of apolipoprotein A-I gene expression in rats fed a high-fat diet. <i>Lipids in Health and Disease</i> , 2012, 11, 77.	1.2	13
388	Associations between Apolipoprotein E Genotype, Diet, Body Mass Index, and Serum Lipids in Lithuanian Adult Population. <i>PLoS ONE</i> , 2012, 7, e41525.	1.1	36
389	The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk. , 2012, , .		12
390	Diet and Dyslipidemias in a Lithuanian Rural Population Aged 25-64: the CINDI Survey. <i>Medicina (Lithuania)</i> , 2012, 48, 30.	0.8	2
391	The prevention and regression of atherosclerotic plaques: emerging treatments. <i>Vascular Health and Risk Management</i> , 2012, 8, 549.	1.0	30
392	Influence of apolipoprotein-E gene on lipid profile, physical activity and body fat relationship. DOI:10.5007/1980-0037.2012v14n2p221. <i>Revista Brasileira De Cineantropometria E Desempenho Humano</i> , 2012, 14, .	0.5	1
393	Application of Total Cardiovascular Risk Estimation in The Management of A Patient with Cardiovascular Risk. <i>University Heart Journal</i> , 2012, 7, 28-34.	0.0	0
394	Dyslipidemia and Cardiovascular Disease. , 0, , .		4
395	Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. <i>EMBO Molecular Medicine</i> , 2012, 4, 251-268.	3.3	172
396	The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China. <i>Endocrine</i> , 2012, 42, 132-138.	1.1	20
397	Women and cardiovascular disease: At a social disadvantage?. <i>Collegian</i> , 2012, 19, 33-37.	0.6	8
398	Design and synthesis of boronic acid inhibitors of endothelial lipase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1397-1401.	1.0	20
399	Can metabolic syndrome predict the vulnerable plaque in patients with stable angina pectoris? Virtual histology-intravascular ultrasound analysis. <i>Journal of Cardiology</i> , 2012, 59, 266-274.	0.8	7
400	Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. <i>Current Atherosclerosis Reports</i> , 2012, 14, 1-10.	2.0	304
401	Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 102-107.	0.8	1

#	ARTICLE	IF	CITATIONS
402	Association of blood lipids, creatinine, albumin, and CRP with socioeconomic status in Malawi. <i>Population Health Metrics</i> , 2013, 11, 4.	1.3	11
403	Lipid profile components and incident cerebrovascular events versus coronary heart disease; the result of 9 years follow-up in Tehran Lipid and Glucose Study. <i>Clinical Biochemistry</i> , 2013, 46, 716-721.	0.8	17
404	Statins in cardiometabolic disease: what makes pitavastatin different?. <i>Cardiovascular Diabetology</i> , 2013, 12, S1.	2.7	17
405	Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis. <i>Gastroenterology</i> , 2013, 145, 1271-1279.e3.	0.6	79
406	Socioeconomic status and dyslipidemia in Korean adults: The 2008-2010 Korea National Health and Nutrition Examination Survey. <i>Preventive Medicine</i> , 2013, 57, 304-309.	1.6	42
407	Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2013, 7, 546-560.	0.6	34
408	Identification of differentially expressed proteins in atherosclerotic aorta and effect of vitamin E. <i>Journal of Proteomics</i> , 2013, 92, 260-273.	1.2	22
409	Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator. <i>Current Atherosclerosis Reports</i> , 2013, 15, 360.	2.0	32
410	Association between habitual dietary intake and lipoprotein subclass profile in healthy young adults. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 1071-1078.	1.1	38
411	Oral contraceptive use and measurable cardiovascular risk factors in Korean women aged 20-50 years: The Fourth Korean National Health and Nutrition Examination Survey 2007-2009 (KNHANES IV). <i>Gynecological Endocrinology</i> , 2013, 29, 707-711.	0.7	3
412	Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis. <i>Atherosclerosis</i> , 2013, 231, 181-186.	0.4	20
413	Evaluation of dyslipidaemia in patients with rheumatoid arthritis in South Indian population. <i>Indian Journal of Rheumatology</i> , 2013, 8, 155-160.	0.2	3
414	Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1834-1841.	1.2	42
415	Evidence for a role of CETP in HDL remodeling and cholesterol efflux: Role of cysteine 13 of CETP. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 1644-1650.	1.2	21
416	Lipids in Women. , 2013, , 965-974.		0
417	High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. <i>Journal of Lipid Research</i> , 2013, 54, 3227-3243.	2.0	132
418	Innovative technique for the direct determination of proteins in calcified aortic valves. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 8781-8787.	1.9	0
419	A new index (CHOLINDEX) in detecting coronary artery disease risk. <i>Anatolian Journal of Cardiology</i> , 2013, 13, 315-9.	0.4	16

#	ARTICLE	IF	CITATIONS
420	Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. <i>International Journal of Epidemiology</i> , 2013, 42, 1754-1771.	0.9	158
421	Risk of Acute Myocardial Infarction. <i>Epidemiology</i> , 2013, 24, 637-642.	1.2	22
422	Recalculation of 23 mouse HDL QTL datasets improves accuracy and allows for better candidate gene analysis. <i>Journal of Lipid Research</i> , 2013, 54, 984-994.	2.0	6
423	Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects. <i>ISRN Vascular Medicine</i> , 2013, 2013, 1-7.	0.7	0
424	Enhanced Lipid Peroxidation and Platelet Activation as Potential Contributors to Increased Cardiovascular Risk in the Low-HDL Phenotype. <i>Journal of the American Heart Association</i> , 2013, 2, e000063.	1.6	28
425	Effect of Licorice Flavonoid Oil on Cholesterol Metabolism in High Fat Diet Rats. <i>Bioscience, Biotechnology and Biochemistry</i> , 2013, 77, 1326-1328.	0.6	9
426	High-Density Lipoprotein Cholesterol Level Is Associated With Fibrous Cap Thickness in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2013, 77, 2982-2989.	0.7	23
427	A Simple Method for Increasing Levels of High-Density Lipoprotein Cholesterol: A Pilot Study of Combination Aerobic- and Resistance-Exercise Training. <i>International Journal of Sport Nutrition and Exercise Metabolism</i> , 2013, 23, 271-281.	1.0	23
428	Niacin Administration Significantly Reduces Oxidative Stress in Patients With Hypercholesterolemia and Low Levels of High-Density Lipoprotein Cholesterol. <i>American Journal of the Medical Sciences</i> , 2013, 345, 195-199.	0.4	31
429	Effects of the <i>Cynanchum wilfordii</i> Ethanol Extract on the Serum Lipid Profile in Hypercholesterolemic Rats. <i>Preventive Nutrition and Food Science</i> , 2013, 18, 157-162.	0.7	25
430	Dietary Squalene Increases High Density Lipoprotein-Cholesterol and Paraoxonase 1 and Decreases Oxidative Stress in Mice. <i>PLoS ONE</i> , 2014, 9, e104224.	1.1	43
431	Cardiac Biomarkers. , 2014, , .		7
432	Not so "good" cholesterol. <i>BMJ, The</i> , 2014, 349, g4664-g4664.	3.0	2
433	Biomarkers in Hypertension and Their Relationship with Myocardial Target-Organ Damage. <i>Current Hypertension Reports</i> , 2014, 16, 502.	1.5	3
434	Cacao Polyphenols Influence the Regulation of Apolipoproteins. , 2014, , 963-970.		0
435	High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 55-63.	0.9	56
436	Comparison of various formulae for estimating low-density lipoprotein cholesterol by a combination of ages and genders in Taiwanese adults. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 113.	0.7	3
437	Dysfunctional HDL: the journey from savior to slayer. <i>Clinical Lipidology</i> , 2014, 9, 49-59.	0.4	15

#	ARTICLE	IF	CITATIONS
438	Lipid Lowering Effect of Punica granatum L. Peel in High Lipid Diet Fed Male Rats. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-5.	0.5	28
439	Determining Information on Cardiology Disease Risk Factors of Disease in Women. International Scholarly Research Notices, 2014, 2014, 1-5.	0.9	3
440	Risks in estimating risk. European Heart Journal, 2014, 35, 537-539.	1.0	10
441	<i>Pollen Typhae</i> total flavone improves insulin resistance in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats. Bioscience, Biotechnology and Biochemistry, 2014, 78, 1738-1742.	0.6	13
442	Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. Journal of Lipid Research, 2014, 55, 2167-2177.	2.0	47
443	Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 913-947.	1.2	85
444	Effect of Aloglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	3.8	206
445	A moderate-fat diet containing pistachios improves emerging markers of cardiometabolic syndrome in healthy adults with elevated LDL levels. British Journal of Nutrition, 2014, 112, 744-752.	1.2	39
446	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. European Journal of Preventive Cardiology, 2014, 21, 866-875.	0.8	18
447	The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Global Cardiology Science & Practice, 2014, 2014, 3.	0.3	16
449	Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrology Dialysis Transplantation, 2014, 29, 1554-1562.	0.4	84
450	Cubilin Maintains Blood Levels of HDL and Albumin. Journal of the American Society of Nephrology: JASN, 2014, 25, 1028-1036.	3.0	71
451	Metabolomics using GC-TOF-MS followed by subsequent GC-FID and HILIC-MS/MS analysis revealed significantly altered fatty acid and phospholipid species profiles in plasma of smokers. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 966, 117-126.	1.2	34
452	Time dependent changes in high density lipoprotein cholesterol and cardiovascular risk. International Journal of Cardiology, 2014, 173, 295-299.	0.8	10
453	Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents. European Journal of Medicinal Chemistry, 2014, 81, 499-509.	2.6	38
454	HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 594-599.	1.1	34
455	Effect of menopause on cardiovascular disease and its risk factors: a 9-year follow-up study. Climacteric, 2014, 17, 164-172.	1.1	29
456	Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart and Vessels, 2014, 29, 35-41.	0.5	24

#	ARTICLE	IF	CITATIONS
457	Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 433-444.	1.4	14
458	How Low an LDL-C Should We Go With Statin Therapy?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 388.	2.0	7
459	Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant Diabetes. <i>Contemporary Diabetes</i> , 2014, , 11-40.	0.0	1
460	Association between serum fatty acids and lipoprotein subclass profile in healthy young adults: Exploring common genetic and environmental factors. <i>Atherosclerosis</i> , 2014, 233, 394-402.	0.4	16
461	HDL-targeted therapies: progress, failures and future. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 445-464.	21.5	289
462	Berry (Poly)phenols and Cardiovascular Health. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 3842-3851.	2.4	146
463	High-Density Lipoprotein. <i>Circulation Research</i> , 2014, 114, 171-182.	2.0	236
464	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. <i>BMJ, The</i> , 2014, 349, g4379-g4379.	3.0	361
465	Development and assessment of a biodegradable solvent cast polyester fabric small diameter vascular graft. <i>Journal of Biomedical Materials Research - Part A</i> , 2014, 102, 1972-1981.	2.1	23
466	Efficacy and Safety of Pitavastatin Versus Simvastatin: A Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2014, 34, 599-608.	1.1	8
467	Association between Apolipoprotein B/Apolipoprotein A-1 and arterial stiffness in metabolic syndrome. <i>Clinica Chimica Acta</i> , 2014, 437, 115-119.	0.5	9
468	Erythrocyte Superoxide Dismutase, Glutathione Peroxidase, and Catalase Activities and Risk of Coronary Heart Disease in Generally Healthy Women: A Prospective Study. <i>American Journal of Epidemiology</i> , 2014, 180, 901-908.	1.6	20
469	Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. <i>Archives of Toxicology</i> , 2014, 88, 1803-1853.	1.9	472
470	High-density lipoprotein as a modulator of platelet and coagulation responses. <i>Cardiovascular Research</i> , 2014, 103, 362-371.	1.8	115
471	HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. <i>Nature Communications</i> , 2014, 5, 3292.	5.8	343
472	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	2.0	12
473	An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 57-63.	2.3	42
474	Inflammatory unbalance of TLR3 and TLR4 in PCI patients with or without type 2 diabetes mellitus. <i>Immunology Letters</i> , 2014, 161, 81-88.	1.1	6

#	ARTICLE	IF	CITATIONS
475	Lipids in health and disease. Nature, 2014, 510, 47-47.	13.7	24
476	HDL-cholesterol in coronary artery disease risk: Function or structure?. Clinica Chimica Acta, 2014, 429, 111-122.	0.5	58
477	Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial. British Journal of Cancer, 2014, 111, 8-16.	2.9	32
478	Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells. Molecular Medicine Reports, 2015, 11, 503-508.	1.1	28
479	New biomarkers for primary mitral regurgitation. Clinical Proteomics, 2015, 12, 25.	1.1	15
480	The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids in Health and Disease, 2015, 14, 127.	1.2	22
481	Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity. Cardiovascular Diabetology, 2015, 14, 79.	2.7	22
482	Distribution of High-Density Lipoprotein Subfractions and Hypertensive Status. Medicine (United Tj ETQq1 1 0.784314 rgBT/Overload	0.4	13
483	Fatty acid moieties have little effect on cholesterol-lowering potency of plant sterol esters. European Journal of Lipid Science and Technology, 2015, 117, 579-588.	1.0	6
484	Clinical research Gestational diabetes mellitus is associated with increased leukocyte peroxisome proliferator-activated receptor β expression. Archives of Medical Science, 2015, 4, 779-787.	0.4	11
485	High Postprandial Triglycerides Serum Levels: Is Obesity a Good Predictor?. Anais Da Academia Brasileira De Ciencias, 2015, 87, 437-445.	0.3	8
486	Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial. PLoS ONE, 2015, 10, e0118393.	1.1	106
487	Is Apolipoprotein B and Small, Dense low density lipoprotein a better marker of cardiovascular risk?. International Journal of Biomedical Research, 2015, 6, 775.	0.1	0
488	High-density lipoprotein cholesterol. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 133-141.	1.2	12
489	Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice. Drug Design, Development and Therapy, 2015, 9, 923.	2.0	8
490	Structural and functional changes in HDL with low grade and chronic inflammation. International Journal of Cardiology, 2015, 188, 111-116.	0.8	60
491	Dyslipidemia and Cardiovascular Disease in Women. Current Cardiology Reports, 2015, 17, 609.	1.3	62
492	Lipoproteins and Cardiovascular Disease Risk. Contemporary Endocrinology, 2015, , 57-65.	0.3	0

#	ARTICLE	IF	CITATIONS
493	The value of apoA-I in predicting heart disease and myocardial infarction. <i>Clinical Lipidology</i> , 2015, 10, 525-541.	0.4	2
494	Mean serum lipid levels in Iranian adult populations: a systematic review and meta-analysis. <i>Clinical Lipidology</i> , 2015, 10, 449-464.	0.4	3
495	Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH). <i>Journal of Clinical Lipidology</i> , 2015, 9, 103-106.	0.6	15
496	An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. <i>Heart</i> , 2015, 101, 553-558.	1.2	27
497	Lipid and lipoprotein measurements and the risk of ischemic vascular events. <i>Neurology</i> , 2015, 84, 472-479.	1.5	62
498	High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men. <i>Atherosclerosis</i> , 2015, 239, 444-450.	0.4	18
499	Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes. <i>Acta Diabetologica</i> , 2015, 52, 611-619.	1.2	12
500	Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: In vitro vs in vivo comparison using anacetrapib and dalcetrapib. <i>European Journal of Pharmacology</i> , 2015, 762, 256-262.	1.7	7
501	Interaction between HDL and inflammation: When the good turns to be bad. <i>International Journal of Cardiology</i> , 2015, 189, 15-17.	0.8	4
502	Cholesterol side chain analogs but not its ether analogs possess cholesterol-lowering activity. <i>Food and Function</i> , 2015, 6, 630-634.	2.1	7
503	Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2015, 116, 1057-1062.	0.7	16
504	Ethnicity and coronary artery disease: the role of high-density lipoprotein – a change in paradigm. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 923-931.	0.6	1
505	Triglyceride-Increasing Alleles Associated with Protection against Type-2 Diabetes. <i>PLoS Genetics</i> , 2015, 11, e1005204.	1.5	21
506	Use of Lipoprotein Particle Measures for Assessing Coronary Heart Disease Risk Post-American Heart Association/American College of Cardiology Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 448-454.	1.1	29
507	Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study. <i>Clinical Research in Cardiology Supplements</i> , 2015, 10, 46-50.	2.0	5
508	Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. <i>Heart</i> , 2015, 101, 847-853.	1.2	15
509	Dysfunctional HDL: From Structure-Function-Relationships to Biomarkers. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 337-366.	0.9	45
510	High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 150-157.	2.7	16

#	ARTICLE	IF	CITATIONS
511	HDL particle subpopulations: Focus on biological function. <i>BioFactors</i> , 2015, 41, 67-77.	2.6	47
512	The severity of the metabolic syndrome increases over time within individuals, independent of baseline metabolic syndrome status and medication use: The Atherosclerosis Risk in Communities Study. <i>Atherosclerosis</i> , 2015, 243, 278-285.	0.4	47
513	The Association of Elevated HDL Levels With Carotid Atherosclerosis in Middle-Aged Women With Untreated Essential Hypertension. <i>Angiology</i> , 2015, 66, 904-910.	0.8	10
514	Prevention of Cardiovascular Diseases. , 2015, , .		1
515	Statins and Cataractsâ€”a Visual Insight. <i>Current Atherosclerosis Reports</i> , 2015, 17, 477.	2.0	14
516	Blockage of hydroxyl group partially abolishes the cholesterol-lowering activity of Î²-sitosterol. <i>Journal of Functional Foods</i> , 2015, 12, 199-207.	1.6	9
517	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	0.9	4
518	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
519	Plasma cholesterol-raising potency of dietary free cholesterol versus cholesteryl ester and effect of Î²-sitosterol. <i>Food Chemistry</i> , 2015, 169, 277-282.	4.2	9
521	11. Cholesterol and fatty acid content and health effects in grass-fed and conventionally raised grain-fed beef. <i>Human Health Handbooks</i> , 2016, , 191-202.	0.1	0
522	Anti-Hyperlipidemia Activity on Neonates and Perinatals. <i>Neonatal and Pediatric Medicine</i> , 2016, 02, .	0.1	0
523	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. <i>Cardiology</i> , 2016, 135, 3-12.	0.6	11
524	Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3763-3770.	2.0	2
525	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	1.0	166
526	Î²-COP as a Component of Transport Vesicles for HDL Apolipoprotein-Mediated Cholesterol Exocytosis. <i>PLoS ONE</i> , 2016, 11, e0151767.	1.1	4
527	Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?. <i>Current Opinion in Lipidology</i> , 2016, 27, 359-366.	1.2	15
528	Hypo-high-density Lipoprotein Cholesterolemia Caused by Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident: Results from the Fukushima Health Management Survey. <i>Internal Medicine</i> , 2016, 55, 1967-1976.	0.3	34
529	Dairy food products: good or bad for cardiometabolic disease?. <i>Nutrition Research Reviews</i> , 2016, 29, 249-267.	2.1	51

#	ARTICLE	IF	CITATIONS
530	Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2761-2772.	1.2	186
531	A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. <i>Journal of Clinical Lipidology</i> , 2016, 10, 228-239.	0.6	5
532	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <i>Journal of Clinical Lipidology</i> , 2016, 10, 472-489.	0.6	219
533	Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy. <i>Journal of Clinical Lipidology</i> , 2016, 10, 116-123.	0.6	3
534	Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease. <i>Medicine (United States)</i> , 2016, 95, 1077-1087.	0.4	10
535	Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus. <i>Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 787-791.	1.1	33
536	Structural Plasticity of Cholesteryl Ester Transfer Protein Assists the Lipid Transfer Activity. <i>Journal of Biological Chemistry</i> , 2016, 291, 19462-19473.	1.6	20
537	Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate. <i>American Journal of the Medical Sciences</i> , 2016, 352, 487-492.	0.4	8
538	Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. <i>Journal of Lipid Research</i> , 2016, 57, 1953-1975.	2.0	365
539	Design, synthesis and biological evaluation of novel cholesteryl ester transfer protein inhibitors bearing a cycloalkene scaffold. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 419-430.	2.6	4
540	High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training. <i>Integrative Medicine Research</i> , 2016, 5, 212-215.	0.7	49
541	Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins. <i>ODYSSEY JAPAN Randomized Controlled Trial</i> . <i>Circulation Journal</i> , 2016, 80, 1980-1987.	0.7	92
542	Genetic markers: Potential candidates for cardiovascular disease. <i>International Journal of Cardiology</i> , 2016, 220, 914-923.	0.8	7
543	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. <i>International Journal of Cardiology</i> , 2016, 225, 268-283.	0.8	17
544	HDL functionality in South Asians as compared to white Caucasians. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 697-705.	1.1	13
545	High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease. <i>Lipids in Health and Disease</i> , 2016, 15, 59.	1.2	19
546	HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications. <i>Lipids in Health and Disease</i> , 2016, 15, 76.	1.2	12
547	Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. <i>Atherosclerosis</i> , 2016, 246, 214-220.	0.4	29

#	ARTICLE	IF	CITATIONS
548	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 275-281.	0.9	9
549	Lipoprotein (a) measurements for clinical application. <i>Journal of Lipid Research</i> , 2016, 57, 526-537.	2.0	214
550	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. <i>Journal of Clinical Lipidology</i> , 2016, 10, 240-264.	0.6	3
551	Interaction of Insulin Resistance and Related Genetic Variants With Triglyceride-Associated Genetic Variants. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 154-161.	5.1	7
552	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 907-921.	1.5	11
553	A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2016, 117, 40-47.	0.7	93
554	Epigenetic and genetic variations at the <i>TNNT1</i> gene locus are associated with HDL-C levels and coronary artery disease. <i>Epigenomics</i> , 2016, 8, 359-371.	1.0	26
555	HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2016, 18, 2.	2.0	46
556	Pre-heparin lipoprotein lipase mass as a potential mediator in the association between adiponectin and HDL-cholesterol in type 2 diabetes. <i>Journal of Clinical and Translational Endocrinology</i> , 2017, 7, 7-11.	1.0	3
557	A systematic review to assess adherence and persistence with statins. <i>Current Medical Research and Opinion</i> , 2017, 33, 769-778.	0.9	65
558	Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. <i>International Journal of Cardiology</i> , 2017, 233, 43-51.	0.8	10
559	Cholesterol-Lowering Activity of Tartary Buckwheat Protein. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 1900-1906.	2.4	73
560	The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 148-153.	1.2	33
561	Structural modulation of gut microbiota in Bama minipigs in response to treatment with a growth-promoting agent, salbutamol. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 5809-5818.	1.7	7
562	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	1.1	766
563	Changes in high-density lipoprotein-carried miRNA contribution to the plasmatic pool after consumption of dietary transfat in healthy men. <i>Epigenomics</i> , 2017, 9, 669-688.	1.0	21
564	Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2017, 40, 674-678.	0.7	24
565	Pitavastatin and HDL: Effects on plasma levels and function(s). <i>Atherosclerosis Supplements</i> , 2017, 27, e1-e9.	1.2	21

#	ARTICLE	IF	CITATIONS
566	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	13.9	593
567	Dyslipidemia management update. <i>Current Opinion in Pharmacology</i> , 2017, 33, 47-55.	1.7	41
568	HDL and the menopause. <i>Current Opinion in Lipidology</i> , 2017, 28, 328-336.	1.2	48
569	Dietary β -sitosterol is more potent in reducing plasma cholesterol than sesamin in hypercholesterolemia hamsters. <i>European Journal of Lipid Science and Technology</i> , 2017, 119, 1600349.	1.0	20
570	Investigating cholesterol metabolism and ageing using a systems biology approach. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 378-391.	0.4	16
571	Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. <i>Journal of Human Genetics</i> , 2017, 62, 453-458.	1.1	15
572	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. <i>BMJ Open</i> , 2017, 7, e014150.	0.8	34
573	Comprehensive primary prevention of cardiovascular disease in women. <i>Clinical Cardiology</i> , 2017, 40, 832-838.	0.7	24
574	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. <i>Progress in Lipid Research</i> , 2017, 68, 57-82.	5.3	63
575	In vivo pharmacodynamic and pharmacokinetic interactions of <i>Hibiscus sabdariffa</i> calyces extracts with simvastatin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 695-703.	0.7	17
576	Usefulness of cardiometabolic index for the estimation of ischemic stroke risk among general population in rural China. <i>Postgraduate Medicine</i> , 2017, 129, 834-841.	0.9	22
577	Advances in quantifying apolipoproteins using LC-MS/MS technology: implications for the clinic. <i>Expert Review of Proteomics</i> , 2017, 14, 869-880.	1.3	23
578	Prevalence of cardiovascular disease risk factors in Tallinn, Estonia. <i>Medicina (Lithuania)</i> , 2017, 53, 268-276.	0.8	6
579	Do We No Longer Need To Worry about Dietary Cholesterol?. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 9931-9933.	2.4	17
580	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1192-1200.e3.	0.6	9
581	Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in rats. <i>European Journal of Pharmacology</i> , 2017, 812, 225-233.	1.7	15
582	Total HDL cholesterol efflux capacity in healthy children – Associations with adiposity and dietary intakes of mother and child. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 70-77.	1.1	9
583	Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 188-195.	1.2	31

#	ARTICLE	IF	CITATIONS
584	Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. <i>Journal of Clinical Lipidology</i> , 2017, 11, 70-79.e1.	0.6	38
585	Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy. <i>Open Heart</i> , 2017, 4, e000731.	0.9	3
586	Multipronged Therapeutic Effects of Chinese Herbal Medicine Qishenyiqi in the Treatment of Acute Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2017, 8, 98.	1.6	30
587	Design, Synthesis, and Biological Evaluation of N,N-Disubstituted-4-Arylthiazole-2-Methylamine Derivatives as Cholesteryl Ester Transfer Inhibitors. <i>Molecules</i> , 2017, 22, 1925.	1.7	4
588	Oxidative stress, antioxidants, and lipid profile in the serum and saliva of individuals with coronary heart disease: is there a link with periodontal health?. <i>Minerva Dental and Oral Science</i> , 2017, 66, 212-225.	0.5	15
589	One-Year Efficacy and Safety of Evolocumab in Japanese Patients—A Pooled Analysis From the Open-Label Extension OSLER Studies. <i>Circulation Journal</i> , 2017, 81, 1029-1035.	0.7	10
590	Do we need to diagnose normal weight metabolic obesity?. <i>Nutrition Obesity & Metabolic Surgery</i> , 2017, 1, 8-11.	0.1	0
591	Cholesterol Levels of Six Fractionated Serum Lipoproteins and its Relevance to Coronary Heart Disease Risk Scores. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 928-939.	0.9	8
592	Degenerated HDL and Its Clinical Implications. , 2017, , 37-63.		0
593	The Relationship between the Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Metabolic Syndrome. <i>Korean Journal of Family Medicine</i> , 2017, 38, 352.	0.4	14
594	Dietary Wheat Bran Oil Is Equally as Effective as Rice Bran Oil in Reducing Plasma Cholesterol. <i>Journal of Agricultural and Food Chemistry</i> , 2018, 66, 2765-2774.	2.4	30
595	Functional genomics and assays of regulatory activity detect mechanisms at loci for lipid traits and coronary artery disease. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 52-59.	1.5	5
596	The therapeutic potential of CETP inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 331-340.	2.4	17
597	HDL-C, ApoA1 and VLDL-TG as biomarkers for the carotid plaque presence in patients with metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 175-179.	1.8	13
598	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. <i>Atherosclerosis</i> , 2018, 269, 92-99.	0.4	11
599	Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. <i>Pharmacoeconomics</i> , 2018, 36, 115-126.	1.7	8
600	Cranberry anthocyanin as an herbal medicine lowers plasma cholesterol by increasing excretion of fecal sterols. <i>Phytomedicine</i> , 2018, 38, 98-106.	2.3	27
601	Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients. <i>International Urology and Nephrology</i> , 2018, 50, 155-165.	0.6	5

#	ARTICLE	IF	CITATIONS
602	Therapeutic Intranasal Vaccine HB-ATV-8 Prevents Atherogenesis and Non-alcoholic Fatty Liver Disease in a Pig Model of Atherosclerosis. <i>Archives of Medical Research</i> , 2018, 49, 456-470.	1.5	7
603	Genetic associations in community context: a mixed model approach identifies a functional variant in the RBP4 gene associated with HDL-C dyslipidemia. <i>BMC Medical Genetics</i> , 2018, 19, 205.	2.1	3
604	Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly – A meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0207947.	1.1	60
605	A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK [®]) lowering cardiovascular disease risk. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 601-609.	0.7	3
606	HDL cholesterol levels and endothelial glycocalyx integrity in treated hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1615-1623.	1.0	18
607	Assessing Baseline and Temporal Changes in Cardiometabolic Risk Using Metabolic Syndrome Severity and Common Risk Scores. <i>Journal of the American Heart Association</i> , 2018, 7, e009754.	1.6	19
608	Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 985-993.	0.9	47
609	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1852-1860.	0.8	21
610	Assessing the added predictive ability of a metabolic syndrome severity score in predicting incident cardiovascular disease and type 2 diabetes: the Atherosclerosis Risk in Communities Study and Jackson Heart Study. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 42.	1.2	21
611	Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. <i>Clinical Therapeutics</i> , 2018, 40, 993-1013.	1.1	17
612	A study on the relationship between waist phenotype, hypertriglyceridemia, coronary artery lesions and serum free fatty acids in adult and elderly patients with coronary diseases. <i>Immunity and Ageing</i> , 2018, 15, 14.	1.8	9
613	Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 17.	2.7	38
614	Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention. <i>Lipids in Health and Disease</i> , 2018, 17, 21.	1.2	2
615	Early formulation development of CKD-519, a new CETP inhibitor, for phase 1 clinical study based on in vitro and in vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2018, 549, 388-396.	2.6	4
616	Estimating the Calibrating Coefficient of the Framingham Score to Predict Risk of Coronary Heart Disease in the Taiwanese Population. <i>International Journal of Gerontology</i> , 2018, , .	0.7	1
617	Plasma metabolites reveal distinct profiles associating with different metabolic risk factors in monozygotic twin pairs. <i>International Journal of Obesity</i> , 2019, 43, 487-502.	1.6	13
618	Human high-density lipoprotein microtranscriptome is unique and suggests an extended role in lipid metabolism. <i>Epigenomics</i> , 2019, 11, 917-934.	1.0	8
619	Dyslipidemia and Meibomian Gland Dysfunction: Utility of Lipidomics and Experimental Prospects with a Diet-Induced Obesity Mouse Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3505.	1.8	24

#	ARTICLE	IF	CITATIONS
620	Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2019, 144, 106345.	1.0	9
621	The correlation between triglyceride to HDL cholesterol ratio and metabolic syndrome, nutrition intake in Korean adults: Korean National Health and Nutrition Examination Survey 2016. <i>Journal of Nutrition and Health</i> , 2019, 52, 268.	0.2	3
622	ApoA-I Mimetic Peptide Reduces Vascular and White Matter Damage After Stroke in Type-2 Diabetic Mice. <i>Frontiers in Neuroscience</i> , 2019, 13, 1127.	1.4	6
623	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. <i>Journal of Drug Assessment</i> , 2019, 8, 167-174.	1.1	1
624	Peripheral Artery Disease and African Americans: Review of the Literature. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	5
625	Manipulation of the Sphingolipid Rheostat Influences the Mediator of Flow-Induced Dilation in the Human Microvasculature. <i>Journal of the American Heart Association</i> , 2019, 8, e013153.	1.6	23
626	Formulation and Characterization of Quercetin-loaded Oil in Water Nanoemulsion and Evaluation of Hypocholesterolemic Activity in Rats. <i>Nutrients</i> , 2019, 11, 244.	1.7	31
627	Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. <i>Hepatology</i> , 2019, 70, 98-107.	3.6	29
628	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. <i>Circulation</i> , 2019, 139, 1472-1482.	1.6	196
629	High-Density Lipoprotein Function and Dysfunction in Health and Disease. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 207-219.	1.3	69
630	The consumption of 12 Eggs per week for 1-year does not alter fasting serum markers of cardiovascular disease in older adults with early macular degeneration. <i>Journal of Nutrition & Intermediary Metabolism</i> , 2019, 15, 35-41.	1.7	5
631	Are dietary amino acids prospectively predicts changes in serum lipid profile?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 1837-1843.	1.8	17
632	Change of HDL by Life Style. , 2019, , 23-118.		0
633	Risk factors of thromboembolism in nonvalvular atrial fibrillation patients with low CHA2DS2-VASc score. <i>Medicine (United States)</i> , 2019, 98, e14549.	0.4	9
634	High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression. <i>Nutrition and Metabolism</i> , 2019, 16, 36.	1.3	82
635	Effects of reduced exposure to cigarette smoking on changes in biomarkers of potential harm in adult smokers: results of combined analysis of two clinical studies. <i>Biomarkers</i> , 2019, 24, 457-468.	0.9	5
636	What's new on therapies for elevated lipoprotein(a). <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 495-499.	1.3	0
637	Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e026603.	0.8	15

#	ARTICLE	IF	CITATIONS
638	Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74 Thrombosis, and Vascular Biology, 2019, 39, 915-924.	1.1	41
639	To test, or not to test: that is the question for the future of lipoprotein(a). Expert Review of Cardiovascular Therapy, 2019, 17, 241-250.	0.6	4
640	Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency. Journal of Clinical Lipidology, 2019, 13, 317-325.	0.6	20
641	Relation of Isolated Low High-Density Lipoprotein Cholesterol to Mortality and Cardiorespiratory Fitness (from the Henry Ford Exercise Testing Project [FIT Project]). American Journal of Cardiology, 2019, 123, 1429-1434.	0.7	3
642	A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab. Journal of the Chinese Medical Association, 2019, 82, 265-271.	0.6	2
643	Triglycerides and endothelial function: molecular biology to clinical perspective. Current Opinion in Lipidology, 2019, 30, 364-369.	1.2	16
644	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. Journal of Clinical Medicine, 2019, 8, 2073.	1.0	15
645	Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application. Journal of Atherosclerosis and Thrombosis, 2019, 26, 111-120.	0.9	20
646	Generalizability and applicability of results obtained from populations of European descent regarding the effect direction and size of HDL-C level-associated genetic variants to the Hungarian general and Roma populations. Gene, 2019, 686, 187-193.	1.0	12
647	Drug Therapy of Dyslipidemia in the Elderly. Drugs and Aging, 2019, 36, 321-340.	1.3	22
648	Subclinical myocardial dysfunction in coronary slow flow phenomenon: Identification by speckle tracking echocardiography. Microcirculation, 2019, 26, e12509.	1.0	8
649	Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 533-543.	0.8	42
650	Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. Journal of Cardiology, 2019, 73, 218-227.	0.8	13
651	Correlation between chronic venous ulcer exudate proteins and clinical profile: A cross-sectional study. Journal of Proteomics, 2019, 192, 280-290.	1.2	24
652	Associations of a metabolic syndrome severity score with coronary heart disease and diabetes in fasting vs. non-fasting individuals. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 92-98.	1.1	9
653	Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2020, 72, 25-33.	1.8	88
654	Aerobic Capacity and the Management of the Patient with Cardiovascular and Pulmonary Limitations. , 2020, , 400-424.		0
655	Genetic linkage of oxidative stress with cardiometabolic traits in an intercross derived from hyperlipidemic mouse strains. Atherosclerosis, 2020, 293, 1-10.	0.4	16

#	ARTICLE	IF	CITATIONS
656	Socio-demographic and modifiable risk factors of diabetes and hypertension among resource constrained patients from rural areas in Mdantsane Township in South Africa. <i>African Health Sciences</i> , 2020, 20, 1344-1354.	0.3	3
657	Lipids and lipoproteins. , 2020, , 487-506.		4
658	Buckwheat proteins: functionality, safety, bioactivity, and prospects as alternative plant-based proteins in the food industry. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 1752-1764.	5.4	39
659	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 658-670.	0.8	9
660	Coronary Atherosclerosis in Women. , 0, , .		0
661	Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). <i>Journal of Clinical Lipidology</i> , 2020, 14, 487-497.e1.	0.6	17
662	Association between dyslipidemia and blood lipids concentration with smoking habits in the Kurdish population of Iran. <i>BMC Public Health</i> , 2020, 20, 673.	1.2	26
663	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 54-93.	6.6	18
664	The impact of gender difference on the relationship between serum high-density lipoprotein level and cardiovascular events in incident dialysis patients: a multicenter prospective cohort study. <i>International Urology and Nephrology</i> , 2020, 52, 1357-1365.	0.6	1
665	Ethanol-mediated upregulation of APOA1 gene expression in HepG2 cells is independent of de novo lipid biosynthesis. <i>Lipids in Health and Disease</i> , 2020, 19, 144.	1.2	8
666	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000943.	1.2	15
667	The association between triglycerides and incident cardiovascular disease: What is "optimal"? <i>Journal of Clinical Lipidology</i> , 2020, 14, 438-447.e3.	0.6	41
668	Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. <i>Journal of Clinical Lipidology</i> , 2020, 14, 695-706.e4.	0.6	15
669	Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2020, 31, 206-231.	1.2	18
670	Effect of Chinese herbal medicine on serum lipids in postmenopausal women with mild dyslipidemia: a randomized, placebo-controlled clinical trial. <i>Menopause</i> , 2020, 27, 801-807.	0.8	2
671	Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2020, 76, 25-29.	0.8	7
672	Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties: An optical coherence tomography-based observational study. <i>Clinica Chimica Acta</i> , 2020, 503, 136-144.	0.5	10
673	Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. <i>Lipids in Health and Disease</i> , 2020, 19, 12.	1.2	29

#	ARTICLE	IF	CITATIONS
674	The cholesterol-lowering activity of miracle fruit (<i>Synsepalum dulcificum</i>). Journal of Food Biochemistry, 2020, 44, e13185.	1.2	13
675	Crossing signals: bioactive lipids in the microvasculature. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1185-H1197.	1.5	9
676	How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 389-405.	2.6	18
677	The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1275-1288.	0.9	17
678	Investigation of Factors of Anti-aging Medical Checkups Affecting HDL Subfractions. Health Evaluation and Promotion, 2021, 48, .	0.0	0
679	Relationship between lipoproteins, thrombosis, and atrial fibrillation. Cardiovascular Research, 2022, 118, 716-731.	1.8	40
680	Levels of Prebeta1 High-Density Lipoprotein Are a Strong Independent Positive Risk Factor for Coronary Heart Disease and Myocardial Infarction: A Meta-Analysis. Journal of the American Heart Association, 2021, 10, e018381.	1.6	5
681	Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. Current Opinion in Cardiology, 2021, 36, 272-280.	0.8	12
682	Role of Hydrogen in Atherosclerotic Disease: From Bench to Bedside. Current Pharmaceutical Design, 2021, 27, 713-722.	0.9	4
684	Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. BMJ Open, 2021, 11, e037457.	0.8	4
685	Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 168, 102282.	1.0	0
686	High hydrostatic pressure extract of mulberry leaves ameliorates hypercholesterolemia via modulating hepatic microRNA-33 expression and AMPK activity in high cholesterol diet fed rats. Food and Nutrition Research, 2021, 65, .	1.2	11
687	High-Density Lipoprotein Cholesterol and the Risk of First Ischemic Stroke in a Chinese Hypertensive Population. Clinical Interventions in Aging, 2021, Volume 16, 801-810.	1.3	8
688	Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein. Journal of Atherosclerosis and Thrombosis, 2021, 28, 703-715.	0.9	4
689	The Role of High-Density Lipoprotein in COVID-19. Frontiers in Pharmacology, 2021, 12, 720283.	1.6	17
691	Structure of Lipoproteins and Their Capacity for Lipid Exchange: Relevance for Development of Atherosclerosis and Its Treatment by HDL Therapy. , 0, , .		1
692	Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis. TH Open, 2021, 05, e295-e302.	0.7	13
693	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Progress in Cardiovascular Diseases, 2021, 67, 65-74.	1.6	23

#	ARTICLE	IF	CITATIONS
694	Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e303-e314.	1.8	5
695	Compared to serum triglyceride alone, the association between serum triglyceride to high-density lipoprotein cholesterol ratio and 10-year cardiovascular disease risk as determined by Framingham risk scores in a large Korean cohort. <i>Clinica Chimica Acta</i> , 2021, 520, 29-33.	0.5	4
696	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPAR α Modulator, Pemafibrate. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 974-996.	0.9	10
697	Lipids, Oxidation, and Cardiovascular Disease. , 2008, , 79-95.		3
698	Lipoprotein(a) as an Emerging Risk Factor for Atherothrombosis. , 2007, , 241-266.		3
699	Lipoprotein Genes and Diet in the Evolution of Human Intelligence and Longevity. , 2003, , 33-67.		3
700	Lipoprotein(a). , 2009, , 130-143.		11
701	Effects of obesity on cholesterol metabolism and its implications for healthy ageing. <i>Nutrition Research Reviews</i> , 2020, 33, 121-133.	2.1	24
703	Red blood cell distribution width and myocardial scar burden in coronary artery disease. <i>Postgraduate Medical Journal</i> , 2017, 93, 607-612.	0.9	9
704	Evidence-Based Medical Management of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 541-553.	1.1	94
705	Trends in Nutritional Intakes and Nutrition-Related Cardiovascular Disease Risk Factors in Lebanon : The Need for Immediate Action. <i>Journal Medical Libanais</i> , 2014, 62, 83-91.	0.0	31
706	Prediction of Risk Factors for Coronary Heart Disease Using Framingham Risk Score in Korean Men. <i>PLoS ONE</i> , 2012, 7, e45030.	1.1	11
707	Overweight and Obesity among Low-Income Muslim Uyghur Women in Far Western China: Correlations of Body Mass Index with Blood Lipids and Implications in Preventive Public Health. <i>PLoS ONE</i> , 2014, 9, e90262.	1.1	15
708	Synergy of circulating miR-212 with markers for cardiovascular risks to enhance estimation of atherosclerosis presence. <i>PLoS ONE</i> , 2017, 12, e0177809.	1.1	16
709	Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesteryl ester transfer protein deficiency. <i>PLoS ONE</i> , 2018, 13, e0190875.	1.1	11
710	High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 55.	0.5	20
711	The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology. <i>European Cardiology Review</i> , 2014, 9, 65.	0.7	6
712	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. <i>European Cardiology Review</i> , 2020, 15, e56.	0.7	10

#	ARTICLE	IF	CITATIONS
713	Effect of pumpkin seed oil on cholesterol fractions and systolic/diastolic blood pressure. Food Science and Technology, 2020, 40, 769-777.	0.8	10
714	Short-Term Intake of Fish Protein Contained in Fish Sausage Improved Lipid Profiles in Hypercholesterolemia Patients: Baseline and Post-Intervention Effects. Japanese Journal of Complementary and Alternative Medicine, 2011, 8, 55-60.	1.0	2
715	ATP-Binding Cassette Transporter A1 Polymorphisms and Haplotypes in Risk of Type 2 Diabetes. Gene, Cell and Tissue, 2016, 4, .	0.2	5
716	CDKN2BAS polymorphisms are associated with coronary heart disease risk a Han Chinese population. Oncotarget, 2016, 7, 82046-82054.	0.8	19
717	Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment. Vascular Health and Risk Management, 2006, 2, 465-475.	1.0	7
718	Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention. Current Medicinal Chemistry, 2019, 26, 1610-1630.	1.2	31
719	Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol. Current Pharmaceutical Design, 2014, 20, 6238-6248.	0.9	15
722	Recent updates in dyslipidemia management: perspectives in stroke-specific situation. Precision and Future Medicine, 2020, 4, 9-20.	0.5	3
723	The relationship between lipoprotein(a) and coronary artery disease, as well as its variable nature following myocardial infarction. Clinical and Investigative Medicine, 2011, 34, 14.	0.3	9
724	Total homocysteine levels and cardiovascular risk factors in healthy Tunisians. Eastern Mediterranean Health Journal, 2011, 17, 937-942.	0.3	4
725	Lipid measures and cardiovascular disease prediction. Disease Markers, 2009, 26, 209-16.	0.6	7
726	Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats. World Journal of Gastroenterology, 2011, 17, 987-95.	1.4	13
727	New insights into ischemic heart disease in women.. Cleveland Clinic Journal of Medicine, 2007, 74, 585-594.	0.6	36
728	The association between fasting serum insulin, apo-lipoproteins level, and severity of coronary artery involvement in non-diabetic patients. Advanced Biomedical Research, 2014, 3, 192.	0.2	4
729	Association between two common polymorphisms (single nucleotide polymorphism -250G/A and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Biomedical Research, 2016, 5, 27.	0.2	8
730	Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. Journal of Family Medicine and Primary Care, 2019, 8, 2249.	0.3	1
731	Association of Serum Lipids with High Blood Pressure and Hypertensionamong Diabetic Patients. Mathematical Regression Models to PredictBlood Pressure from Lipids. An Experience from 12-year Follow Up ofmore than 9000 Patients' Cohort. General Medicine (Los Angeles, Calif), 2017, 05, .	0.2	3
732	HDL-C as a new therapeutic target in the treatment of dyslipidemia. Medicine Science, 2012, 1, 141.	0.0	2

#	ARTICLE	IF	CITATIONS
733	Lower High-Density Lipoprotein Cholesterol is a Significant and Independent Risk for Coronary Artery Disease in Japanese Men. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 792-798.	0.9	15
734	Evaluating the Effect of the rs2229238 and the rs4845625 Interleukin 6 Receptor Gene Polymorphisms on Body Mass Index and the Risk of Type 2 Diabetes in an Iranian Study Population. <i>International Journal of High Risk Behaviors & Addiction</i> , 2016, 5, .	0.1	4
735	Amlodipine attenuates oxidative stress in the heart and blood of high-cholesterol diet rabbits. <i>Cardiovascular Journal of Africa</i> , 2012, 23, 18-22.	0.2	8
736	The Effect of Natural Mixture Supplementation on Histopathological and Histomorphometrical aspects in High Fat Diet-induced Obese Mice. <i>The Korea Journal of Herbology</i> , 2012, 27, 53-58.	0.2	7
738	Gender and Its Impact on Risk Factors for Cardiovascular Disease. , 2004, , 193-214.		2
740	Effects of the Extract of Hoelen on Serum Lipid Profiles in Mice. <i>Journal of the Korean Society of Food Science and Nutrition</i> , 2006, 35, 1005-1009.	0.2	4
741	Management of Elevated Low-Density Lipoprotein Cholesterol. <i>Fundamental and Clinical Cardiology</i> , 2006, , 255-294.	0.0	0
742	Lipid Abnormalities in Polycystic Ovary Syndrome. , 2007, , 79-97.		0
743	Hangbisan, Sulfur-based Oriental Medicine, Lowers the Blood Cholesterol Level of ob/ob Obese Mice. <i>Journal of the Korean Society of Food Science and Nutrition</i> , 2007, 36, 27-31.	0.2	2
744	Coronary Risk Factors: An Overview. , 2007, , 2609-2630.		3
745	Acute Coronary Syndrome in Women and the Elderly. , 2008, , 212-228.		0
746	The Problems of Advanced Ischemic Heart Disease. , 2009, , 1-12.		0
747	Endocannabinoid Receptor Blockers. , 2009, , 339-351.		0
749	Risk Assessment for Complications of Diabetes Mellitus. , 2009, , 195-241.		0
750	Prevention of Cardiovascular Disease. , 2009, , 403-436.		0
751	Effects of Isoflavone Supplementation on Lipid Profiles and Antioxidant Systems in Rats Fed with Cholesterol Diet. <i>Journal of Life Science</i> , 2010, 20, 1683-1690.	0.2	2
752	Lipoprotein(a). , 2011, , 173-179.		0
753	Advanced Lipid Testing. , 2011, , 77-103.		0

#	ARTICLE	IF	CITATIONS
755	Association between change in HDL-C and vascular events in patients treated with statins: Report from the UK general practice research database. <i>World Journal of Cardiovascular Diseases</i> , 2012, 02, 64-73.	0.0	0
756	The Pathophysiology of Coronary Artery Disease. , 2012, , 1-28.		1
757	The Buffering Role of HDL in Balancing the Effects of Hypercoagulable State in Type 2 Diabetes. <i>Journal of Applied Sciences</i> , 2012, 12, 745-752.	0.1	2
758	The influence of high-density lipoprotein cholesterol on maximal lipid core burden indexing thin cap fibrous atheroma lesions as assessed by near infrared spectroscopy. <i>Cardiology Journal</i> , 2021, 28, 887-895.	0.5	4
759	Strain-Blood Pressure Index for Evaluation of Early Changes in Elasticity of Anterior Tibial Artery in Patients with Type 2 Diabetes Mellitus. <i>Medical Science Monitor</i> , 2014, 20, 2414-2420.	0.5	1
760	A Closer Look at Cardioprotective Function of HDL: Revise the HDL “Cholesterol Hypothesis?”. <i>Indonesian Biomedical Journal</i> , 2014, 6, 17.	0.2	0
761	Ethanol extract of <i>Plantago asiatica</i> L. controls intracellular fat accumulation and lipid metabolism in 3T3-L1 Adipocytes. <i>The Korea Journal of Herbology</i> , 2014, 29, 77-82.	0.2	3
762	Cholesteryl Ester Transfer Protein Inhibitors “Future Soon to be REVEALed. <i>European Cardiology Review</i> , 2015, 10, 64.	0.7	0
763	Relationship Between Blood Pressure and Lipid Profile on Obese Children. <i>American Journal of Health Research</i> , 2015, 3, 198.	0.3	1
764	Association between LDL, Apolipoprotein-B Apolipoprotein A-I and Lipoprotein(a) and Severity of Coronary Artery Disease Based on Coronary Angiography. <i>Journal of Biosciences and Medicines</i> , 2015, 03, 53-61.	0.1	1
765	Cardiovascular Disease in Women: An Update. , 2015, , 129-141.		0
766	Serum Lipid Profile of Adrenaline-induced Hypertensive Rats Administered with Aqueous Extract of <i>Arachis hypogea</i> Testa. <i>Journal of Complementary and Alternative Medical Research</i> , 2016, 1, 1-10.	0.4	0
768	The Anti-obesity Effects of <i>Platycodi Radix</i> , Combination of <i>Platycodi Radix</i> and <i>Cyperi Rhizoma</i> on Obesity Induced by High Fat Diet. <i>The Korea Journal of Herbology</i> , 2016, 31, 1-11.	0.2	1
769	A Novel Heart Disease Prediction System Based on Quantum Neural Network Using Clinical Parameters. <i>Annual Research & Review in Biology</i> , 2017, 14, 1-10.	0.4	1
770	The High Density Lipoprotein Cholesterol Hypothesis Revisited. <i>Indonesian Biomedical Journal</i> , 2018, 10, 84-103.	0.2	0
771	Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. <i>Endocrinology and Metabolism</i> , 2020, 35, 367-376.	1.3	9
772	The role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13693.	1.7	14
773	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 615-636.	0.0	0

#	ARTICLE	IF	CITATIONS
774	Association between Metabolic Syndrome and Triglyceride to HDL-Cholesterol Ratio according to Smoking Status in Korean Men Aged 60 Years and Over. Korean Journal of Clinical Geriatrics, 2020, 21, 110-116.	0.3	1
775	Cardiovascular Disease in Women: Focus on Lipid Management. Contemporary Cardiology, 2021, , 467-487.	0.0	0
776	Primary Prevention of Cardiovascular Disease Guidelines. Contemporary Cardiology, 2021, , 653-672.	0.0	0
777	Bisflavonoids fraction from Araucaria bidwilli Hook., reverses hyperlipidemia induced atherosclerosis in high-fat diet induced hyperlipidemia. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	1
778	Acute Running and Coronary Heart Disease Risk Markers in Male Cigarette Smokers and Nonsmokers: A Randomized Crossover Trial. Medicine and Science in Sports and Exercise, 2021, 53, 1021-1032.	0.2	6
779	Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vascular Health and Risk Management, 2007, 3, 845-52.	1.0	40
780	Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction. Vascular Health and Risk Management, 2007, 3, 1045-51.	1.0	3
781	Multiple lipid scoring system for prediction of coronary heart disease risk: application to African Americans. Journal of the National Medical Association, 2006, 98, 1740-5.	0.6	0
782	Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Texas Heart Institute Journal, 2008, 35, 388-94.	0.1	6
783	The independent relationship between triglycerides and coronary heart disease. Vascular Health and Risk Management, 2009, 5, 89-95.	1.0	54
785	Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Texas Heart Institute Journal, 2013, 40, 288-9.	0.1	5
786	Effects of kampo formulas on the progression of hypercholesterolemia and Fatty liver induced by high-cholesterol diet in rats. Yonago Acta Medica, 2014, 57, 147-58.	0.3	8
787	Haplotype Analysis of PPAR α Gene Polymorphisms and the Lipoprotein (a) Level. Iranian Journal of Public Health, 2018, 47, 973-979.	0.3	1
788	The Relationship Between Premature Myocardial Infarction with TC/HDL-C Ratio Subgroups in a Multiple Risk Factor Model. Advanced Journal of Emergency Medicine, 2019, 3, e24.	0.7	1
789	Fibronectin-containing High-Density Lipoprotein is Associated with Cancer Cell Adhesion and Proliferation. Kobe Journal of Medical Sciences, 2020, 66, E40-E48.	0.2	1
790	Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study. Family Practice, 2022, , .	0.8	1
791	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis, 2022, 343, 28-50.	0.4	12
792	Association of high-density lipoprotein cholesterol and periodontitis severity in Chinese elderly: a cross-sectional study. Clinical Oral Investigations, 2022, 26, 4753-4759.	1.4	5

#	ARTICLE	IF	CITATIONS
793	Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2022, 13, 865863.	1.5	6
795	The relationships between erythrocyte membrane n-6 to n-3 polyunsaturated fatty acids ratio and blood lipids and C-reactive protein in Chinese adults: an observational study. <i>Biomedical and Environmental Sciences</i> , 2011, 24, 234-42.	0.2	3
796	Post-Stroke Administration of L-4F Promotes Neurovascular and White Matter Remodeling in Type-2 Diabetic Stroke Mice. <i>Frontiers in Neurology</i> , 2022, 13, 863934.	1.1	4
797	Abnormal glucose regulation in Chinese patients with coronary artery disease: a gender analysis. <i>Journal of Cardiothoracic Surgery</i> , 2022, 17, 94.	0.4	1
798	Lipoprotein(a) and ethnicities. <i>Atherosclerosis</i> , 2022, 349, 42-52.	0.4	29
799	Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	19
800	Associations of Socioeconomic Status and Healthy Lifestyle With Incidence of Dyslipidemia: A Prospective Chinese Governmental Employee Cohort Study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	10
801	Angiotensin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. <i>Clinical Pharmacology: Advances and Applications</i> , 0, Volume 14, 49-59.	0.8	5
802	Selenium and vitamin B6 cosupplementation improves dyslipidemia and fatty liver syndrome by SIRT1/SREBP-1c pathway in hyperlipidemic Sprague-Dawley rats induced by high-fat diet. <i>Nutrition Research</i> , 2022, 106, 101-118.	1.3	7
803	Sexual Dysfunction as a Harbinger of Cardiovascular Disease in Postmenopausal Women: How Far Are We?. <i>Journal of Sexual Medicine</i> , 2022, 19, 1321-1332.	0.3	12
804	Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study. <i>Current Problems in Cardiology</i> , 2023, 48, 101395.	1.1	6
805	Low-density lipoprotein cholesterol in oldest old with acute myocardial infarction: Is lower the better?. <i>Age and Ageing</i> , 2022, 51, .	0.7	4
806	Associations Between Life-Course Lipid Trajectories and Subclinical Atherosclerosis in Midlife. <i>JAMA Network Open</i> , 2022, 5, e2234862.	2.8	12
807	Correlations Between Coronary Artery Disease, Coronary Artery Calcium Score, and Lipoprotein(a) Level in Korea. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 981-987.	0.9	0
808	Saturated fats, dairy foods and cardiovascular health: No longer a curious paradox?. <i>Nutrition Bulletin</i> , 2022, 47, 407-422.	0.8	17
809	Influence of acute and chronic intermittent hypoxic-hyperoxic exposure prior to aerobic exercise on cardiovascular risk factors in geriatric patients—a randomized controlled trial. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	1
810	Dynamic Resistance Exercise Alters Blood ApoA-I Levels, Inflammatory Markers, and Metabolic Syndrome Markers in Elderly Women. <i>Healthcare (Switzerland)</i> , 2022, 10, 1982.	1.0	0
811	U-shaped relationship between apolipoprotein A1 levels and mortality risk in men and women. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 293-304.	0.8	5

#	ARTICLE	IF	CITATIONS
812	High-density lipoprotein revisited: biological functions and clinical relevance. <i>European Heart Journal</i> , 2023, 44, 1394-1407.	1.0	51
813	Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL. <i>Journal of Lipid Research</i> , 2023, 64, 100319.	2.0	0
814	Discovering comorbid diseases using an inter-disease interactivity network based on biobank-scale PheWAS data. <i>Bioinformatics</i> , 2023, 39, .	1.8	5
815	New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3. <i>Journal of Lipid and Atherosclerosis</i> , 2023, 12, 23.	1.1	6
816	Fully automated immunoassay for cholesterol uptake capacity to assess high-density lipoprotein function and cardiovascular disease risk. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
817	Dairy foods and cardiometabolic diseases: an update and a reassessment of the impact of SFA. <i>Proceedings of the Nutrition Society</i> , 2023, 82, 329-345.	0.4	5
818	Disease-modifying vs symptomatic treatments: Splitting over lumping. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 187-209.	1.0	5
819	Insulin resistance and cardiovascular disease. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311645.	0.4	28